Endothelin

Anthony P Davenport, Kelly A Hyndman, Neeraj Dhaun, Christopher Southan, Donald E Kohan, Jennifer S Pollock, David M Pollock, David J Webb, Janet J Maguire, Anthony P Davenport, Kelly A Hyndman, Neeraj Dhaun, Christopher Southan, Donald E Kohan, Jennifer S Pollock, David M Pollock, David J Webb, Janet J Maguire

Abstract

The endothelins comprise three structurally similar 21-amino acid peptides. Endothelin-1 and -2 activate two G-protein coupled receptors, ETA and ETB, with equal affinity, whereas endothelin-3 has a lower affinity for the ETA subtype. Genes encoding the peptides are present only among vertebrates. The ligand-receptor signaling pathway is a vertebrate innovation and may reflect the evolution of endothelin-1 as the most potent vasoconstrictor in the human cardiovascular system with remarkably long lasting action. Highly selective peptide ETA and ETB antagonists and ETB agonists together with radiolabeled analogs have accurately delineated endothelin pharmacology in humans and animal models, although surprisingly no ETA agonist has been discovered. ET antagonists (bosentan, ambrisentan) have revolutionized the treatment of pulmonary arterial hypertension, with the next generation of antagonists exhibiting improved efficacy (macitentan). Clinical trials continue to explore new applications, particularly in renal failure and for reducing proteinuria in diabetic nephropathy. Translational studies suggest a potential benefit of ETB agonists in chemotherapy and neuroprotection. However, demonstrating clinical efficacy of combined inhibitors of the endothelin converting enzyme and neutral endopeptidase has proved elusive. Over 28 genetic modifications have been made to the ET system in mice through global or cell-specific knockouts, knock ins, or alterations in gene expression of endothelin ligands or their target receptors. These studies have identified key roles for the endothelin isoforms and new therapeutic targets in development, fluid-electrolyte homeostasis, and cardiovascular and neuronal function. For the future, novel pharmacological strategies are emerging via small molecule epigenetic modulators, biologicals such as ETB monoclonal antibodies and the potential of signaling pathway biased agonists and antagonists.

Copyright © 2016 The Author(s).

Figures

Fig. 1.
Fig. 1.
Long lasting vasoconstrictor response to 10 nM ET-1 in human mammary artery is maintained for over 2 hours but can be reversed by the physiologic antagonist nitric oxide derived from a nitric oxide donor (A) or by the ETA antagonist PD156707 but not the ETB antagonist BQ788 (B).
Fig. 2.
Fig. 2.
Schematic diagram showing the sequences of ET, Big ET precursors and sarafotoxin peptides. Amino acids that differ between ET-1 and mature peptides or between Big ET-1 and precursors are shown in blue. Labeling of [125I] radioligands at Tyr residues are shown by a filled red circle. Residues that are thought from X-ray crystallography to be aligned as a stripe as a result of a secondary helical structure secondary helical structure are indicated with a star (Janes et al., 1994; Orry and Wallace, 2000). These residues have also been shown experimentally to be crucial for binding (Huggins et al., 1993). Arrows indicate the site for cleavage of Big ETs to mature peptides: between Trp21-Val22 amino acids for Big ET-1 and ET-2 and between Trp21-Ile22 for ET-1 and for Big ET-3.
Fig. 3.
Fig. 3.
Schematic diagram illustrating synthesis of ET peptides and interaction with receptors. ET isoforms are synthesized by a three-step process: Messenger RNA encodes a prepro-peptide that after a proteolytic cleavage initial of the signal peptidase to yield the propeptide is further cleaved by furin to Big ET precursors. Synthesis of ET-1 has been studied in the most detail. Transformation to the mature, biologically active ET-1 is mainly by the action of ECE-1 at pH 7 but also by ECE-2 at pH 5.5 within endothelial cells. On release from endothelial cells, about one in five molecules of Big ET-1 escape conversion but further processing to ET-1 may occur by smooth muscle ECE or via alternative pathways catalyzed by chymase for ET-1. It is inferred that ET-2 from endothelial cells is synthesized by a similar pathway. ET-3 is not released from human endothelial cells but is also synthesized in other cells by ECE-1 with evidence for an additional pathway, KELL. ET-1 is metabolized by NEP to inactive metabolites. ETs mediate their actions via two GPCRs ETA or ETB and the recommended agonists and antagonists that are most widely used are indicated together with ECE inhibitors.
Fig. 4.
Fig. 4.
ET-1 is synthesized in human endothelial cells by a dual secretory pathway. ET-1 is continuously released from the small vesicles of the constitutive pathway to interact with ET receptors to contribute to vasomotor tone. ET-1 is also released from the regulated pathway in response to external stimuli from Weibel-Palade bodies that are unique to endothelial cells. In the human vasculature, ET-1 released abluminally from endothelial cells, interacts mainly with ETA receptors on the underlying smooth muscle, with a small population of ETB receptors also mediating constriction in some but not all vessels. In animals, vasoconstriction can be via ETB or a mixture of both depending on the vascular bed. The ET-1/ETA complex undergoes internalization to the endosome before recycling of the receptor to the cell surface and provides a mechanism whereby ETA antagonist can reverse an ET-1 response. Some ET-1 may also interact with endothelial ETB receptors in an autocrine manner and limit the constrictor response by the release of vasodilators such as nitric oxide. ET-1/ETB complex is internalized and degraded to the lysosome; as a result ETB antagonists are unable to displace receptor bound ligand. Low levels of ET-1 and Big ET-1 that has escaped conversion can also be detected in the plasma. Big ET-1 can also undergo further conversion by smooth muscle ECE to the mature peptide.
Fig. 5.
Fig. 5.
Schematic diagram of the human ETA receptor. Experimental mutations altering receptor function are shown in red. Potential sites for translational modifications are shown as phosphorylation (yellow), glycosylation (gray), and palmitoylation (purple). Diagrams generated using http://tools.gpcr.org/ (Isberg et al., 2014).
Fig. 6.
Fig. 6.
Schematic diagram of the human ETB receptor. Naturally occurring mutation reported in patients with Hirschsprung disease (blue), experimental mutations altering receptor function (red). Potential sites for translational modifications as shown as phosphorylation (yellow), glycosylation (gray), and palmitoylation (purple). Green indicates both a phosphoraylation and site experimentally mutated. Diagrams generated using http://tools.gpcr.org/ (Isberg et al., 2014).
Fig. 7.
Fig. 7.
Relative expression of mRNA encoding ETA (Ednra) or ETB (Ednrb) receptors in 41 adult tissues. (Graphs constructed using data from Regard et al., 2008).
Fig. 8.
Fig. 8.
Ratio of ETA to ETB densities measured by saturation binding assays in the human brain, kidney, lung, liver, and heart and smooth muscle layer of the vessels from each organ.
Fig. 9.
Fig. 9.
Comparison of the selectivity of ET ligands for native ETA and ETB receptors measured in the same competition binding assay against [125I]-ET-1. This assay uses human heart, which expresses both subtypes, resulting in a biphasic competition curve. Measurement of the affinity (the equilibrium dissociation constant or KD) of each compound at the two receptor sub-types can be accurately determined using non-linear iterative curve fitting. Comparison of the two affinities provides a measure of the selectivity for each subtype (Maguire and Davenport, 2012).
Fig. 10.
Fig. 10.
Spectrum of selectivity of antagonists for ETA versus ETB receptors as reported by the companies that discovered the compounds mainly based on measuring affinity constants in separate competition assays against [125I]-ET-1 using human recombinant ETA versus ETB receptors. Antagonists are classified as either selective for one subtype or alternatively as mixed antagonists that block both receptors. The classification is usually made by the manufacturer, but there is no agreed definition and there are anomalies. We proposed that antagonists that are ETA-selective should display more than 100-fold selectivity for the ETA subtype and those that block both ETA and ETB (mixed antagonists) should demonstrate less than 100-fold ETA selectivity. The rational for this classification is based on receptor occupancy where a concentration can be calculated to block virtually all ETA receptors but not ETB for in vitro studies. The threshold is indicated by the lower dashed line. It is difficult to achieve exact plasma concentration in vivo and to achieve selectivity; compounds with at least two orders of magnitude are more useful. Bosentan, ambrisentan, and macitentan are currently approved for clinical use and are highlighted. Note that the manufacturers of macitentan classify the antagonist as a mixed antagonist although it displays ETA selectivity. Sparsentan is a dual ETA/angiotensin II receptor type 1 receptor antagonist (modified from Maguire and Davenport, 2014).
Fig. 11.
Fig. 11.
Pipeline of ET receptor antagonists measured by papers in PubMed (blue bars), papers with ChEMBL entries in Europe PubMed Central (red bars) and patents (green bars) in PATENTSCOPE with ET receptor antagonists combined with patent classification C07D (code for medicinal chemistry) (Bento et al. 2014).
Fig. 12.
Fig. 12.
Three-dimensional alignments shown as a top view (A) and the side view (B) of the 11-molecule cluster of ET antagonists using ChemAxon Marvin tool at default settings to perform a flexible overlap of atoms via on-the-fly adjustments. The following 11 were selected as having high affinity: peptide antagonist FR139317 and nonpeptide antagonists, A127722, ambrisentan, avosentan, darusentan, macitentan, PD156707, PD164333, SB234551, sitaxentan, and zibotentan. Top (C) and side view (D) of a three-molecule cluster of ETB peptide antagonist, BQ788, and nonpeptide antagonists A192621 and RO468443.

References

    1. Abe Y, Sakurai T, Yamada T, Nakamura T, Yanagisawa M, Goto K. (2000) Functional analysis of five endothelin-B receptor mutations found in human Hirschsprung disease patients. Biochem Biophys Res Commun 275:524–531.
    1. Abrahams W. (2001) Progress in Clinical Trials: ENCOR. Clin Cardiol 24:481–483.
    1. Adiarto S, Heiden S, Vignon-Zellweger N, Nakayama K, Yagi K, Yanagisawa M, Emoto N. (2012) ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci 91:651–657.
    1. Adner M, Cardell LO, Sjöberg T, Ottosson A, Edvinsson L. (1996) Contractile endothelin-B (ETB) receptors in human small bronchi. Eur Respir J 9:351–355.
    1. Adner M, Jansen I, Edvinsson L. (1994) Endothelin-A receptors mediate contraction in human cerebral, meningeal and temporal arteries. J Auton Nerv Syst 49 (Suppl):S117–S121.
    1. Ahmed M, Nencetti S, Mazzoni MR, Porchia F, Antonelli F, Lapucci A. (2008) Allosteric inhibition of [(125I)] ET-1 binding to ET(A) receptors by aldoxime and hydroxamic acid derivatives. Med Chem 4:298–308.
    1. Ahn D, Ge Y, Stricklett PK, Gill P, Taylor D, Hughes AK, Yanagisawa M, Miller L, Nelson RD, Kohan DE. (2004) Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 114:504–511.
    1. Ahn K, Sisneros AM, Herman SB, Pan SM, Hupe D, Lee C, Nikam S, Cheng XM, Doherty AM, Schroeder RL, et al. (1998) Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun 243:184–190.
    1. Albany C, Hahn NM. (2014) Novel bone-targeting agents in prostate cancer. Prostate Cancer Prostatic Dis 17:112–118.
    1. Allard B, Wijkhuisen A, Borrull A, Deshayes F, Priam F, Lamourette P, Ducancel F, Boquet D, Couraud JY. (2013) Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor. MAbs 5:56–69.
    1. Allcock GH, Venema RC, Pollock DM. (1998) ETA receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats. Am J Physiol 275:R245–R252.
    1. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL. (2004) Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110:2233–2240.
    1. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Lüscher TF, EARTH investigators (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364:347–354.
    1. Andresen J, Shafi NI, Bryan RM., Jr (2006) Endothelial influences on cerebrovascular tone. J Appl Physiol (1985) 100:318–327.
    1. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730–732.
    1. Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, Kojo H, Notsu Y, Ono T, Nakanishi S. (1993) Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol 43:127–131.
    1. Arfian N, Emoto N, Vignon-Zellweger N, Nakayama K, Yagi K, Hirata K. (2012) ET-1 deletion from endothelial cells protects the kidney during the extension phase of ischemia/reperfusion injury. Biochem Biophys Res Commun 425:443–449.
    1. Arvidsson K, Nemoto T, Mitsui Y, Ohashi S, Nakanishi H. (1998) The solution structure of human endothelin-2 a 1H-NMR and CD study. Eur J Biochem 257:380–388.
    1. Asano T, Ikegaki I, Suzuki Y, Satoh S, Shibuya M. (1989) Endothelin and the production of cerebral vasospasm in dogs. Biochem Biophys Res Commun 159:1345–1351.
    1. Babaei S, Picard P, Ravandi A, Monge JC, Lee TC, Cernacek P, Stewart DJ. (2000) Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 48:158–167.
    1. Bacon CR, Davenport AP. (1996) Endothelin receptors in human coronary artery and aorta. Br J Pharmacol 117:986–992.
    1. Baetge G, Gershon MD. (1989) Transient catecholaminergic (TC) cells in the vagus nerves and bowel of fetal mice: relationship to the development of enteric neurons. Dev Biol 132:189–211.
    1. Baetge G, Pintar JE, Gershon MD. (1990a) Transiently catecholaminergic (TC) cells in the bowel of the fetal rat: precursors of noncatecholaminergic enteric neurons. Dev Biol 141:353–380.
    1. Baetge G, Schneider KA, Gershon MD. (1990b) Development and persistence of catecholaminergic neurons in cultured explants of fetal murine vagus nerves and bowel. Development 110:689–701.
    1. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV. (2006) Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 48:286–293.
    1. Bagnato A, Loizidou M, Pflug BR, Curwen J, Growcott J. (2011) Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 163:220–233.
    1. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. (2010) Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 56:824–830.
    1. Barhoumi T, Briet M, Kasal DA, Fraulob-Aquino JC, Idris-Khodja N, Laurant P, Paradis P, Schiffrin EL. (2014) Erythropoietin-induced hypertension and vascular injury in mice overexpressing human endothelin-1: exercise attenuated hypertension, oxidative stress, inflammation and immune response. J Hypertens 32:784–794.
    1. Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, Jaisser F. (2016) Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. J Am Soc Nephrol 27:398–404.
    1. Barst RJ. (2007) A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag 3:11–22.
    1. Barton M, Haudenschild CC, d’Uscio LV, Shaw S, Münter K, Lüscher TF. (1998) Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 95:14367–14372.
    1. Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE. (2006) Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) 231:653–695.
    1. Bauersachs J, Fraccarollo D, Galuppo P, Widder J, Ertl G. (2000) Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure. Cardiovasc Res 47:142–149.
    1. Bax WA, Bruinvels AT, van Suylen RJ, Saxena PR, Hoyer D. (1993) Endothelin receptors in the human coronary artery, ventricle and atrium. A quantitative autoradiographic analysis. Naunyn Schmiedebergs Arch Pharmacol 348:403–410.
    1. Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE, Yanagisawa M. (1994) Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79:1277–1285.
    1. Becker A, Dowdle EB, Hechler U, Kauser K, Donner P, Schleuning WD. (1993) Bibrotoxin, a novel member of the endothelin/sarafotoxin peptide family, from the venom of the burrowing asp Atractaspis bibroni. FEBS Lett 315:100–103.
    1. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, Krüger FA, Light Y, Mak L, McGlinchey S, et al. (2014) The ChEMBL bioactivity database: an update. Nucleic Acids Res 42:D1083–D1090.
    1. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. (2007) Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 26:63–69.
    1. Best PJM, McKenna CJ, Hasdai D, Holmes DRJ, Jr, Lerman A. (1999) Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 99:1747–1752.
    1. Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. (2009) Endothelin receptor antagonism and cancer. Eur J Clin Invest 39 (Suppl 2):74–77.
    1. Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, et al. (2007) Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 9:760–769.
    1. Blais V, Fugère M, Denault JB, Klarskov K, Day R, Leduc R. (2002) Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. FEBS Lett 524:43–48.
    1. Blandin V, Vigne P, Breittmayer JP, Frelin C. (2000) Allosteric inhibition of endothelin ETA receptors by 3, 5-dibromosalicylic acid. Mol Pharmacol 58:1461–1469.
    1. Blaugrund E, Pham TD, Tennyson VM, Lo L, Sommer L, Anderson DJ, Gershon MD. (1996) Distinct subpopulations of enteric neuronal progenitors defined by time of development, sympathoadrenal lineage markers and Mash-1-dependence. Development 122:309–320.
    1. Bloch KD, Hong CC, Eddy RL, Shows TB, Quertermous T. (1991) cDNA cloning and chromosomal assignment of the endothelin 2 gene: vasoactive intestinal contractor peptide is rat endothelin 2. Genomics 10:236–242.
    1. Boesen EI. (2015) Endothelin receptors, renal effects and blood pressure. Curr Opin Pharmacol 21:25–34.
    1. Boulanger C, Lüscher TF. (1990) Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85:587–590.
    1. Bourgeois C, Robert B, Rebourcet R, Mondon F, Mignot TM, Duc-Goiran P, Ferré F. (1997) Endothelin-1 and ETA receptor expression in vascular smooth muscle cells from human placenta: a new ETA receptor messenger ribonucleic acid is generated by alternative splicing of exon 3. J Clin Endocrinol Metab 82:3116–3123.
    1. Braasch I, Schartl M. (2014) Evolution of endothelin receptors in vertebrates. Gen Comp Endocrinol 209:21–34.
    1. Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J, Singer M, Glen RC, Wilkinson IB, Davenport AP. (2015) Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension 65:834–840.
    1. Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, Attramadal H. (2000) Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem 275:17596–17604.
    1. Breu V, Clozel M, Burri K, Hirth G, Neidhart W, Ramuz H. (1996) In vitro characterisation of Ro 46-8443, the first non-peptide antagonist selective for the endothelin ETB receptor. FEBS Lett 383:37–41.
    1. Briyal S, Shepard C, Gulati A. (2014) Endothelin receptor type B agonist, IRL-1620, prevents beta amyloid (Aβ) induced oxidative stress and cognitive impairment in normal and diabetic rats. Pharmacol Biochem Behav 120:65–72.
    1. Bruderer S, Hopfgartner G, Seiberling M, Wank J, Sidharta PN, Treiber A, Dingemanse J. (2012) Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 42:901–910.
    1. Bugaj V, Mironova E, Kohan DE, Stockand JD. (2012) Collecting duct-specific endothelin B receptor knockout increases ENaC activity. Am J Physiol Cell Physiol 302:C188–C194.
    1. Bugaj V, Pochynyuk O, Mironova E, Vandewalle A, Medina JL, Stockand JD. (2008) Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct. Am J Physiol Renal Physiol 295:F1063–F1070.
    1. Cacioppo JA, Koo Y, Lin PC, Gal A, Ko C. (2015) Generation and characterization of an endothelin-2 iCre mouse. Genesis 53:245–256.
    1. Cai J, Liu L, Hong KH, Wang P, Li L, Cao M, Sun C, Wu X, Zong X, Chen J, et al. (2015) Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity. Bioorg Med Chem 23:657–667.
    1. Cameron IT, Plumpton C, Champeney R, van Papendorp C, Ashby MJ, Davenport AP. (1993) Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium. J Reprod Fertil 98:251–255.
    1. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO, 3rd, Panza JA. (1999) Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33:753–758.
    1. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB, Atrasentan Phase III Study Group Institutions (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959–1966.
    1. Carlini R, Obialo CI, Rothstein M. (1993) Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 6:103–107.
    1. Castañares C, Redondo-Horcajo M, Magán-Marchal N, ten Dijke P, Lamas S, Rodríguez-Pascual F. (2007) Signaling by ALK5 mediates TGF-β-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J Cell Sci 120:1256–1266.
    1. Chandrashekar K, Juncos LA. (2014) Endothelin antagonists in diabetic nephropathy: back to basics. J Am Soc Nephrol 25:869–871.
    1. Chang I, Bramall AN, Baynash AG, Rattner A, Rakheja D, Post M, Joza S, McKerlie C, Stewart DJ, McInnes RR, et al. (2013) Endothelin-2 deficiency causes growth retardation, hypothermia, and emphysema in mice. J Clin Invest 123:2643–2653.
    1. Cheng HF, Su YM, Yeh JR, Chang KJ. (1993) Alternative transcript of the nonselective-type endothelin receptor from rat brain. Mol Pharmacol 44:533–538.
    1. Chester AH, Yacoub MH. (2014) The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract 2014:62–78.
    1. Chow M, Dumont AS, Kassell NF. (2002) Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 51:1333–1341, discussion 1342.
    1. Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, Rosanò L. (2014) β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells. Life Sci 118:179–184.
    1. Clapéron A, Rose C, Gane P, Collec E, Bertrand O, Ouimet T. (2005) The Kell protein of the common K2 phenotype is a catalytically active metalloprotease, whereas the rare Kell K1 antigen is inactive. Identification of novel substrates for the Kell protein. J Biol Chem 280:21272–21283.
    1. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. (1989) Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 257:H2033–H2035.
    1. Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T, Kumada M, Hammer RE, Yanagisawa M. (1998) Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 125:813–824.
    1. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, Hirth G, Löffler BM, Müller M, Neidhart W, et al. (1993) Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365:759–761.
    1. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassal JM, Hirth G, Muller M, Neidhart W, et al. (1994) Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228–235.
    1. Clozel M, Maresta A, Humbert M. (2013) Endothelin receptor antagonists. Handbook Exp Pharmacol 218:199–227.
    1. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. (1992) Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85:504–509.
    1. Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, et al. (2013) A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). Gynecol Oncol 130:31–37.
    1. Cole DJ, Matsumura JS, Drummond JC, Schultz RL, Wong MH. (1991) Time- and pressure-dependent changes in blood-brain barrier permeability after temporary middle cerebral artery occlusion in rats. Acta Neuropathol 82:266–273.
    1. Compeer MG, Janssen GM, De Mey JG. (2013) Endothelin-1 and endothelin-2 initiate and maintain contractile responses by different mechanisms in rat mesenteric and cerebral arteries. Br J Pharmacol 170:1199–1209.
    1. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823.
    1. Cowburn PJ, Cleland JG, McDonagh TA, McArthur JD, Dargie HJ, Morton JJ. (2005) Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur J Heart Fail 7:37–42.
    1. Cozza EN, Chiou S, Gomez-Sanchez CE. (1992) Endothelin-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol 262:R85–R89.
    1. Cramer H, Müller-Esterl W, Schroeder C. (1997) Subtype-specific desensitization of human endothelin ETA and ETB receptors reflects differential receptor phosphorylation. Biochemistry 36:13325–13332.
    1. Cramer H, Schmenger K, Heinrich K, Horstmeyer A, Böning H, Breit A, Piiper A, Lundstrom K, Müller-Esterl W, Schroeder C. (2001) Coupling of endothelin receptors to the ERK/MAP kinase pathway. Roles of palmitoylation and G(alpha)q. Eur J Biochem 268:5449–5459.
    1. Culshaw GJ, MacIntyre IM, Dhaun N, Webb DJ. (2015) Endothelin in nondiabetic chronic kidney disease: preclinical and clinical studies. Semin Nephrol 35:176–187.
    1. Dahlöf B, Gustafsson D, Hedner T, Jern S, Hansson L. (1990) Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens 8:811–817.
    1. Dashwood MR, Timm M, Muddle JR, Shah D, Tippins JR, Kaski JC. (1995) [3H]bosentan binding to human coronary artery: functional correlates. J Cardiovasc Pharmacol 26 (Suppl 3):S376–S379.
    1. Davenport AP. (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54:219–226.
    1. Davenport AP, Kuc RE. (2000) Cellular expression of isoforms of endothelin-converting enzyme-1 (ECE-1c, ECE-1b and ECE-1a) and endothelin-converting enzyme-2. J Cardiovasc Pharmacol 36(5, Suppl 1)S12–S14.
    1. Davenport AP, Kuc RE. (2004) Down-regulation of ETA receptors in ETB receptor-deficient mice. J Cardiovasc Pharmacol 44 (Suppl 1):S276–S278.
    1. Davenport AP, Maguire JJ. (2006) Endothelin. Handbook Exp Pharmacol 176:295–329.
    1. Davenport AP, Morton AJ. (1991) Binding sites for 125I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells. Brain Res 554:278–285.
    1. Davenport AP, D’Orléans-Juste P, Godfraind T, Maguire JJ, Ohlstein EH, Ruffolo RR. (2015) Endothelin receptors, introduction. IUPHAR/BPS Guide to PHARMACOLOGY, ).
    1. Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 65:967–986.
    1. Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, Nunez DJ, Capper SJ, Brown MJ. (1990) A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Lond) 78:261–264.
    1. Davenport AP, Hoskins SL, Kuc RE, Plumpton C. (1996) Differential distribution of endothelin peptides and receptors in human adrenal gland. Histochem J 28:779–789.
    1. Davenport AP, Kuc RE, Fitzgerald F, Maguire JJ, Berryman K, Doherty AM. (1994a) [125I]-PD151242: a selective radioligand for human ETA receptors. Br J Pharmacol 111:4–6.
    1. Davenport AP, Kuc RE, Hoskins SL, Karet FE, Fitzgerald F. (1994b) [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature. Br J Pharmacol 113:1303–1310.
    1. Davenport AP, Kuc RE, Maguire JJ, Harland SP. (1995a) ETA receptors predominate in the human vasculature and mediate constriction. J Cardiovasc Pharmacol 26 (Suppl 3):S265–S267.
    1. Davenport AP, Kuc RE, Plumpton C, Mockridge JW, Barker PJ, Huskisson NS. (1998) Endothelin-converting enzyme in human tissues. Histochem J 30:359–374.
    1. Davenport AP, Morton AJ, Brown MJ. (1991) Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney. J Cardiovasc Pharmacol 17 (Suppl 7):S152–S155.
    1. Davenport AP, Nunez DJ, Hall JA, Kaumann AJ, Brown MJ. (1989) Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol 13 (Suppl 5):S166–S170.
    1. Davenport AP, O’Reilly G, Kuc RE. (1995b) Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol 114:1110–1116.
    1. Davenport AP, O’Reilly G, Molenaar P, Maguire JJ, Kuc RE, Sharkey A, Bacon CR, Ferro A. (1993) Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol 22 (Suppl 8):S22–S25.
    1. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, Wharton J. (2002) ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165:398–405.
    1. de la Monte SM, Quertermous T, Hong CC, Bloch KD. (1995) Regional and maturation-associated expression of endothelin 2 in rat gastrointestinal tract. J Histochem Cytochem 43:203–209.
    1. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, et al. (2014) The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25:1083–1093.
    1. Devesly P, Phillips PE, Johns A, Rubanyi G, Parker-Botelho LH. (1990) Receptor kinetics differ for endothelin-1 and endothelin-2 binding to Swiss 3T3 fibroblasts. Biochem Biophys Res Commun 172:126–134.
    1. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, et al. (2013) A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344:708–717.
    1. Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ. (2007a) Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 22:3228–3234.
    1. Dhaun N, Goddard J, Webb DJ. (2006) The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17:943–955.
    1. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ. (2011) Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57:772–779.
    1. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. (2009a) Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54:113–119.
    1. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. (2009b) Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease. Hypertension 54:e19–e20.
    1. Dhaun N, Pollock DM, Goddard J, Webb DJ. (2007b) Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28:573–579.
    1. Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R, Koopman PA. (2004) Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 94:237–239.
    1. Dimond P, Carlson K, Bouvier M, Gerard C, Xu L, Covic L, Agarwal A, Ernst OP, Janz JM, Schwartz TW, et al. (2011) G protein-coupled receptor modulation with pepducins: moving closer to the clinic. Ann N Y Acad Sci 1226:34–49.
    1. Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. (2014) Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf 13:391–405.
    1. Doetschman T, Gregg RG, Maeda N, Hooper ML, Melton DW, Thompson S, Smithies O. (1987) Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 330:576–578.
    1. Don GW, Joseph F, Celermajer DS, Corte TJ. (2012) Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. Intern Med J 42:1351–1354.
    1. Donato AJ, Lesniewski LA, Stuart D, Walker AE, Henson G, Sorensen L, Li D, Kohan DE. (2014) Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development. Life Sci 118:238–243.
    1. D'Orleans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, Simard E. (2008) Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies. Vascular pharmacology 49:51–62.
    1. D’Orléans-Juste P, Télémaque S, Claing A. (1991) Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro. Br J Pharmacol 104:440–444.
    1. Douglas SA, Hiley CR. (1990) Endothelium-dependent vascular activities of endothelin-like peptides in the isolated superior mesenteric arterial bed of the rat. Br J Pharmacol 101:81–88.
    1. Drawnel FM, Archer CR, Roderick HL. (2013) The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br J Pharmacol 168:296–317.
    1. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084.
    1. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. (1996) Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94:1578–1584.
    1. d’Uscio LV, Barton M, Shaw S, Lüscher TF. (2002) Chronic ET(A) receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. Cardiovasc Res 53:487–495.
    1. Elferink JG, de Koster BM. (1996) The effect of endothelin-2 (ET-2) on migration and changes in cytosolic free calcium of neutrophils. Naunyn Schmiedebergs Arch Pharmacol 353:130–135.
    1. Elshourbagy NA, Adamou JE, Gagnon AW, Wu HL, Pullen M, Nambi P. (1996) Molecular characterization of a novel human endothelin receptor splice variant. J Biol Chem 271:25300–25307.
    1. Emoto N, Yanagisawa M. (1995) Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270:15262–15268.
    1. Endemann DH, Schiffrin EL. (2004) Endothelial dysfunction. J Am Soc Nephrol 15:1983–1992.
    1. Ergul S, Parish DC, Puett D, Ergul A. (1996) Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28:652–655.
    1. Evans MJ, Kaufman MH. (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154–156.
    1. Evans NJ, Walker JW. (2008a) Sustained Ca2+ signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. Can J Physiol Pharmacol 86:526–535.
    1. Evans NJ, Walker JW. (2008b) Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization. Biophys J 95:483–492.
    1. Farhat H, Allen BG. (2004) Salicylic acid alters endothelin-1 binding in intact adult rat ventricular myocytes. Biochem Cell Biol 82:728–738.
    1. Fecteau MH, Honoré JC, Plante M, Labonté J, Rae GA, D’Orléans-Juste P. (2005) Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension 46:87–92.
    1. Ferro CJ, Haynes WG, Hand MF, Webb DJ. (2002) Forearm vasoconstriction to endothelin-1 is impaired, but constriction to sarafotoxin 6c and vasodilatation to BQ-123 unaltered, in patients with essential hypertension. Clin Sci (Lond) 103 (Suppl 48):53S–58S.
    1. Ferro CJ, Haynes WG, Johnston NR, Lomax CC, Newby DE, Webb DJ. (1997) The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction. Br J Clin Pharmacol 44:377–383.
    1. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. (1998) Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97:2323–2330.
    1. Flondell-Sité D, Lindblad B, Gottsäter A. (2010) High levels of endothelin (ET)-1 and aneurysm diameter independently predict growth of stable abdominal aortic aneurysms. Angiology 61:324–328.
    1. Flynn MA, Haleen SJ, Welch KM, Cheng XM, Reynolds EE. (1998) Endothelin B receptors on human endothelial and smooth-muscle cells show equivalent binding pharmacology. J Cardiovasc Pharmacol 32:106–116.
    1. Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M, Harmar AJ. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev 57:279–288.
    1. Franceschini R, Gandolfo C, Cataldi A, Del Sette M, Rolandi A, Corsini G, Rolandi E, Barreca T. (2001) Twenty-four-hour endothelin-1 secretory pattern in stroke patients. Biomed Pharmacother 55:272–276.
    1. Freedman BI, Langefeld CD, Lohman KK, Bowden DW, Carr JJ, Rich SS, Wagenknecht LE. (2005) Relationship between albuminuria and cardiovascular disease in Type 2 diabetes. J Am Soc Nephrol 16:2156–2161.
    1. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. (1994b) Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 199:1461–1465.
    1. Fukuroda T, Kobayashi M, Ozaki S, Yano M, Miyauchi T, Onizuka M, Sugishita Y, Goto K, Nishikibe M. (1994. a) Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol 76:1976–1982.
    1. Galie N, Naeije R, Burgess G, and Dilleen M (2009) 3-year survival of patients treated with sitaxentan sodium (Thelin®) for pulmonary arterial hypertension. Eur Heart J, 30: 262.
    1. Gandhi CR, Kang Y, De Wolf A, Madariaga J, Aggarwal S, Scott V, Fung J. (1996) Altered endothelin homeostasis in patients undergoing liver transplantation. Liver Transpl Surg 2:362–369.
    1. Gardiner SM, Kemp PA, Bennett T. (1992a) Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats. Br J Pharmacol 107:584–590.
    1. Gardiner SM, Kemp PA, Compton AM, Bennett T. (1992b) Coeliac haemodynamic effects of endothelin-1, endothelin-3, proendothelin-1 [1-38] and proendothelin-3 [1-41] in conscious rats. Br J Pharmacol 106:483–488.
    1. Gardiner SM, Kemp PA, March JE, Bennett T. (1994) Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br J Pharmacol 112:823–830.
    1. Gariepy CE, Cass DT, Yanagisawa M. (1996) Null mutation of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color. Proc Natl Acad Sci USA 93:867–872.
    1. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. (2000) Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105:925–933.
    1. Gariepy CE, Williams SC, Richardson JA, Hammer RE, Yanagisawa M. (1998) Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease. J Clin Invest 102:1092–1101.
    1. Gasic S, Wagner OF, Vierhapper H, Nowotny P, Waldhäusl W. (1992) Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol 19:176–180.
    1. Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O. (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 7:e47662.
    1. Ge Y, Ahn D, Stricklett PK, Hughes AK, Yanagisawa M, Verbalis JG, Kohan DE. (2005a) Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality. Am J Physiol Renal Physiol 288:F912–F920.
    1. Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE. (2006) Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291:F1274–F1280.
    1. Ge Y, Bagnall A, Stricklett PK, Webb D, Kotelevtsev Y, Kohan DE. (2008a) Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Renal Physiol 295:F1635–F1640.
    1. Ge Y, Huang Y, Kohan DE. (2008b) Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure. Can J Physiol Pharmacol 86:329–336.
    1. Ge Y, Strait KA, Stricklett PK, Yang T, Kohan DE. (2007) Role of prostaglandins in collecting duct-derived endothelin-1 regulation of blood pressure and water excretion. Am J Physiol Renal Physiol 293:F1805–F1810.
    1. Ge Y, Stricklett PK, Hughes AK, Yanagisawa M, Kohan DE. (2005b) Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol Renal Physiol 289:F692–F698.
    1. Giaid A, Gibson SJ, Herrero MT, Gentleman S, Legon S, Yanagisawa M, Masaki T, Ibrahim NB, Roberts GW, Rossi ML, et al. (1991) Topographical localisation of endothelin mRNA and peptide immunoreactivity in neurones of the human brain. Histochemistry 95:303–314.
    1. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732–1739.
    1. Givertz MM, Colucci WS, LeJemtel TH, Gottlieb SS, Hare JM, Slawsky MT, Leier CV, Loh E, Nicklas JM, Lewis BE. (2000) Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 101:2922–2927.
    1. Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb DJ. (2004a) Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 15:2601–2610.
    1. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ. (2004b) Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109:1186–1193.
    1. Grant JS, White K, MacLean MR, Baker AH. (2013) MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci 70:4479–4494.
    1. Grant K, Loizidou M, Taylor I. (2003) Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 88:163–166.
    1. Green DS, Rupasinghe C, Warburton R, Wilson JL, Sallum CO, Taylor L, Yatawara A, Mierke D, Polgar P, Hill N. (2013) A cell permeable peptide targeting the intracellular loop 2 of endothelin B receptor reduces pulmonary hypertension in a hypoxic rat model. PLoS One 8:e81309.
    1. Gregan B, Jürgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, Rosenthal W, Oksche A. (2004) Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 279:27679–27687.
    1. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. (2004) A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 64:2461–2468.
    1. Grimshaw MJ, Naylor S, Balkwill FR. (2002a) Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther 1:1273–1281.
    1. Grimshaw MJ, Wilson JL, Balkwill FR. (2002b) Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 32:2393–2400.
    1. Gu H, Zou YR, Rajewsky K. (1993) Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73:1155–1164.
    1. Guimarães CL, Calixto JB, Rae GA. (1992) Potent constrictor actions of endothelin-1, endothelin-2, and endothelin-3 in rat isolated portal vein. Hypertension 19(2, Suppl)II79–II86.
    1. Gulati A, Sunila ES, Kuttan G. (2012) IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in Dalton’s Lymphoma Ascites tumor model. Arzneimittelforschung 62:14–17.
    1. Halcox JP, Nour KR, Zalos G, Quyyumi AA. (2001) Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res 89:969–976.
    1. Halcox JP, Nour KR, Zalos G, Quyyumi AA. (2007) Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B. Hypertension 49:1134–1141.
    1. Hand MF, Haynes WG, Webb DJ. (1999) Reduced endogenous endothelin-1-mediated vascular tone in chronic renal failure. Kidney Int 55:613–620.
    1. Hardebo JE, Kåhrström J, Owman C, Salford LG. (1989) Endothelin is a potent constrictor of human intracranial arteries and veins. Blood Vessels 26:249–253.
    1. Harland SP, Kuc RE, Pickard JD, Davenport AP. (1995) Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas. J Cardiovasc Pharmacol 26 (Suppl 3):S408–S411.
    1. Harland SP, Kuc RE, Pickard JD, Davenport AP. (1998) Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Neurosurgery 43:890–898, discussion 898–899.
    1. Harrison-Bernard LM, de Garavilla L, Bivona BJ. (2013) Enhanced vascular chymase-dependent conversion of endothelin in the diabetic kidney. Ochsner J 13:49–55.
    1. Hashido K, Gamou T, Adachi M, Tabuchi H, Watanabe T, Furuichi Y, Miyamoto C. (1992) Truncation of N-terminal extracellular or C-terminal intracellular domains of human ETA receptor abrogated the binding activity to ET-1. Biochem Biophys Res Commun 187:1241–1248.
    1. Hasue F, Kuwaki T, Kisanuki YY, Yanagisawa M, Moriya H, Fukuda Y, Shimoyama M. (2005) Increased sensitivity to acute and persistent pain in neuron-specific endothelin-1 knockout mice. Neuroscience 130:349–358.
    1. Hathaway CK, Grant R, Hagaman JR, Hiller S, Li F, Xu L, Chang AS, Madden VJ, Bagnell CR, Rojas M, et al. (2015) Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade. Proc Natl Acad Sci USA 112:5141–5146.
    1. Hay DW, Luttmann MA, Hubbard WC, Undem BJ. (1993) Endothelin receptor subtypes in human and guinea-pig pulmonary tissues. Br J Pharmacol 110:1175–1183.
    1. Hay DW, Luttmann MA, Pullen MA, Nambi P. (1998) Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype? J Pharmacol Exp Ther 284:669–677.
    1. Haynes WG, Webb DJ. (1993) Endothelium-dependent modulation of responses to endothelin-I in human veins. Clin Sci (Lond) 84:427–433.
    1. Haynes WG, Webb DJ. (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344:852–854.
    1. Haynes WG, Ferro CJ, O’Kane KP, Somerville D, Lomax CC, Webb DJ. (1996) Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93:1860–1870.
    1. Haynes WG, Strachan FE, Webb DJ. (1995a) Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 92:357–363.
    1. Haynes WG, Strachan FE, Gray GA, Webb DJ. (1995b) Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. J Cardiovasc Pharmacol 26 (Suppl 3):S40–S43.
    1. Heiden S, Vignon-Zellweger N, Masuda S, Yagi K, Nakayama K, Yanagisawa M, Emoto N. (2014) Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice. PLoS One 9:e88730.
    1. Heimlich JB, Speed JS, Bloom CJ, O’Connor PM, Pollock JS, Pollock DM. (2015) ET-1 increases reactive oxygen species following hypoxia and high-salt diet in the mouse glomerulus. Acta Physiol (Oxf) 213:722–730.
    1. Hemsén A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM. (1995) Metabolism of Big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept 55:287–297.
    1. Henry PJ, Rigby PJ, Self GJ, Preuss JM, Goldie RG. (1990) Relationship between endothelin-1 binding site densities and constrictor activities in human and animal airway smooth muscle. Br J Pharmacol 100:786–792.
    1. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. (1985) Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 248:C550–C556.
    1. Hinterhuber L, Graziadei IW, Kähler CM, Jaschke W, Vogel W. (2004) Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2:1039–1042.
    1. Hocher B, Dembowski C, Slowinski T, Friese ST, Schwarz A, Siren AL, Neumayer HH, Thöne-Reineke C, Bauer C, Nafz B, et al. (2001) Impaired sodium excretion, decreased glomerular filtration rate and elevated blood pressure in endothelin receptor type B deficient rats. J Mol Med (Berl) 78:633–641.
    1. Hocher B, Liefeldt L, Thöne-Reineke C, Orzechowski HD, Distler A, Bauer C, Paul M. (1996) Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 28:196–201.
    1. Hocher B, Rohmeiss P, Thöne-Reineke C, Schwarz A, Burst V, van der Woude F, Bauer C, Theuring F. (1998) Apoptosis in kidneys of endothelin-1 transgenic mice. J Cardiovasc Pharmacol 31 (Suppl 1):S554–S556.
    1. Hocher B, Schwarz A, Slowinski T, Bachmann S, Pfeilschifter J, Neumayer HH, Bauer C. (2004) In-vivo interaction of nitric oxide and endothelin. J Hypertens 22:111–119.
    1. Hocher B, Thöne-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, et al. (1997) Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99:1380–1389.
    1. Horstmeyer A, Cramer H, Sauer T, Müller-Esterl W, Schroeder C. (1996) Palmitoylation of endothelin receptor A. Differential modulation of signal transduction activity by post-translational modification. J Biol Chem 271:20811–20819.
    1. Hocher B, Paul M. (2000) Transgenic animal models for the analysis of the renal endothelin system. Nephrol Dial Transplant 15:935–937.
    1. Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A, Yanagisawa M. (1994) Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79:1267–1276.
    1. Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, Suga S, Nakanishi S, Imura H. (1992) Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem 267:18797–18804.
    1. Houde M, Jamain MD, Labonté J, Desbiens L, Pejler G, Gurish M, Takai S, D’Orléans-Juste P. (2013) Pivotal role of mouse mast cell protease 4 in the conversion and pressor properties of Big-endothelin-1. J Pharmacol Exp Ther 346:31–37.
    1. Howard PG, Plumpton C, Davenport AP. (1992) Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens 10:1379–1386.
    1. Huggins JP, Pelton JT, Miller RC. (1993) The structure and specificity of endothelin receptors: their importance in physiology and medicine. Pharmacol Ther 59:55–123.
    1. Hung VK, Chen SM, Tai LW, Chen AY, Chung SK, Cheung CW. (2012) Over-expression of endothelin-1 in astrocytes, but not endothelial cells, ameliorates inflammatory pain response after formalin injection. Life Sci 91:618–622.
    1. Hung VK, Tai LW, Qiu Q, Luo X, Wong KL, Chung SK, Cheung CW. (2014) Over-expression of astrocytic ET-1 attenuates neuropathic pain by inhibition of ERK1/2 and Akt(s) via activation of ETA receptor. Mol Cell Neurosci 60:26–35.
    1. Hyndman KA, Pollock JS. (2013) Nitric oxide and the A and B of endothelin of sodium homeostasis. Current opinion in nephrology and hypertension 22:26–31.
    1. Hyndman KA, Bugaj V, Mironova E, Stockand JD, Pollock JS. (2015) NOS1-dependent negative feedback regulation of the epithelial sodium channel in the collecting duct. Am J Physiol Renal Physiol 308:F244–F251.
    1. Hyndman KA, MacDonell AH, Pollock JS. (2012) Extracellular signal-regulated kinases 1/2 signaling pathways are not involved in endothelin regulation of mouse inner medullary collecting duct nitric oxide production. Life Sci 91:578–582.
    1. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, et al. (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198–202.
    1. Ieda M, Fukuda K, Hisaka Y, Kimura K, Kawaguchi H, Fujita J, Shimoda K, Takeshita E, Okano H, Kurihara Y, et al. (2004) Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. J Clin Invest 113:876–884.
    1. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, et al. (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327:736–745.
    1. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M, Yano M. (1992a) Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 50:247–255.
    1. Ihara M, Saeki T, Fukuroda T, Kimura S, Ozaki S, Patel AC, Yano M. (1992b) A novel radioligand [125I]BQ-3020 selective for endothelin (ETB) receptors. Life Sci 51:PL47–PL52.
    1. Ihara M, Yamanaka R, Ohwaki K, Ozaki S, Fukami T, Ishikawa K, Towers P, Yano M. (1995) [3H]BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype. Eur J Pharmacol 274:1–6.
    1. Ikadai H, Fujita Y, Agematsu Y, Ikamachi T. (1979) Observation of congenital aganglionosis rat (Hirschsprung’s disease) and its genetical analysis. in Japanese Cong Anom 19:31–36.
    1. Ikeda S, Emoto N, Alimsardjono H, Yokoyama M, Matsuo M. (2002) Molecular isolation and characterization of novel four subisoforms of ECE-2. Biochem Biophys Res Commun 293:421–426.
    1. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. (1989) The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 264:14954–14959.
    1. Irani S, Salajegheh A, Smith RA, Lam AK. (2014) A review of the profile of endothelin axis in cancer and its management. Crit Rev Oncol Hematol 89:314–321.
    1. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR, et al. (2015) Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. Nat Commun 6:7495, 1–11. ( 10.1038/ncomms8495).
    1. Isberg V, Vroling B, van der Kant R, Li K, Vriend G, Gloriam D. (2014) GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res 42:D422–D425.
    1. Ishida N, Tsujioka K, Tomoi M, Saida K, Mitsui Y. (1989) Differential activities of two distinct endothelin family peptides on ileum and coronary artery. FEBS Lett 247:337–340.
    1. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, et al. (1994) Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91:4892–4896.
    1. Ito S, Juncos LA, Nushiro N, Johnson CS, Carretero OA. (1991) Endothelium-derived relaxing factor modulates endothelin action in afferent arterioles. Hypertension 17:1052–1056.
    1. Iwashima A, Kobayashi M, Saida K, Kagamu H, Ohashi S, Arakawa M, Mitsui Y. (1997) Contraction and intracellular calcium-ion elevation of cultured human aortic smooth muscle cells by endothelin-1, vasoactive intestinal contractor (VIC) and the derivatives. In Vitro Cell Dev Biol Anim 33:751–756.
    1. James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA. (2010) Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 106:966–973.
    1. Janes RW, Peapus DH, Wallace BA. (1994) The crystal structure of human endothelin. Nat Struct Biol 1:311–319.
    1. Jeng AY, Mulder P, Kwan AL, Battistini B. (2002) Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol 80:440–449.
    1. Johansson S, Povlsen GK, Edvinsson L. (2012) Expressional changes in cerebrovascular receptors after experimental transient forebrain ischemia. PLoS One 7:e41852.
    1. Johnson GD, Stevenson T, Ahn K. (1999) Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem 274:4053–4058.
    1. Johnström P, Aigbirhio FI, Clark JC, Downey SP, Pickard JD, Davenport AP. (2000) Syntheses of the first endothelin-A- and -B-selective radioligands for positron emission tomography. J Cardiovasc Pharmacol 36(5, Suppl 1)S58–S60.
    1. Johnström P, Fryer TD, Richards HK, Barret O, Clark JC, Ohlstein EH, Pickard JD, Davenport AP. (2004) In vivo imaging of cardiovascular endothelin receptors using the novel radiolabelled antagonist [18F]-SB209670 and positron emission tomography (microPET). J Cardiovasc Pharmacol 44 (Suppl 1):S34–S38.
    1. Johnström P, Fryer TD, Richards HK, Harris NG, Barret O, Clark JC, Pickard JD, Davenport AP. (2005) Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol 144:115–122.
    1. Johnström P, Fryer TD, Richards HK, Maguire JJ, Clark JC, Pickard JD, Davenport AP. (2010) Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver. Br J Pharmacol 159:812–819.
    1. Johnström P, Rudd JH, Richards HK, Fryer TD, Clark JC, Weissberg PL, Pickard JD, Davenport AP. (2006) Imaging endothelin ET(B) receptors using [18F]-BQ3020: in vitro characterization and positron emission tomography (microPET). Exp Biol Med (Maywood) 231:736–740.
    1. Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, et al. (2011) Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension 57:755–763.
    1. Kalk P, Thöne-Reineke C, Schwarz A, Godes M, Bauer C, Pfab T, Hocher B. (2009) Renal phenotype of ET-1 transgenic mice is modulated by androgens. Eur J Med Res 14:55–58.
    1. Karam H, Bruneval P, Clozel JP, Löffler BM, Bariéty J, Clozel M. (1995) Role of endothelin in acute renal failure due to rhabdomyolysis in rats. J Pharmacol Exp Ther 274:481–486.
    1. Karet FE, Davenport AP. (1996) Localization of endothelin peptides in human kidney. Kidney Int 49:382–387.
    1. Kedzierski RM, Grayburn PA, Kisanuki YY, Williams CS, Hammer RE, Richardson JA, Schneider MD, Yanagisawa M. (2003) Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol. Mol Cell Biol 23:8226–8232.
    1. Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, et al. (2007) A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs 25:247–252.
    1. Kelland NF, Bagnall AJ, Morecroft I, Gulliver-Sloan FH, Dempsie Y, Nilsen M, Yanagisawa M, Maclean MR, Kotelevtsev YV, Webb DJ. (2010a) Endothelial ET(B) limits vascular remodelling and development of pulmonary hypertension during hypoxia. J Vasc Res 47:16–22.
    1. Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, et al. (2010b) Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol 88:644–651.
    1. Kelly-Cobbs AI, Harris AK, Elgebaly MM, Li W, Sachidanandam K, Portik-Dobos V, Johnson M, Ergul A. (2011) Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J Pharmacol Exp Ther 337:9–15.
    1. Kenakin T. (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296–302.
    1. Kim FY, Barnes EA, Ying L, Chen C, Lee L, Alvira CM, Cornfield DN. (2015) Pulmonary artery smooth muscle cell endothelin-1 expression modulates the pulmonary vascular response to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 308:L368–L377.
    1. Kim W, Essalmani R, Szumska D, Creemers JW, Roebroek AJ, D’Orleans-Juste P, Bhattacharya S, Seidah NG, Prat A. (2012) Loss of endothelial furin leads to cardiac malformation and early postnatal death. Mol Cell Biol 32:3382–3391.
    1. Kiowski W, Lüscher TF, Linder L, Bühler FR. (1991) Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 83:469–475.
    1. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. (1995) Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346:732–736.
    1. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, Kedzierski RM, Hammer RE, Yanagisawa H, Williams SC, et al. (2010) Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 56:121–128.
    1. Kittikulsuth W, Looney SW, Pollock DM. (2013) Endothelin ET(B) receptors contribute to sex differences in blood pressure elevation in angiotensin II hypertensive rats on a high-salt diet. Clin Exp Pharmacol Physiol 40:362–370.
    1. Kittikulsuth W, Pollock JS, Pollock DM. (2011) Sex differences in renal medullary endothelin receptor function in angiotensin II hypertensive rats. Hypertension 58:212–218.
    1. Kloog Y, Ambar I, Sokolovsky M, Kochva E, Wollberg Z, Bdolah A. (1988) Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science 242:268–270.
    1. Knott PG, D’Aprile AC, Henry PJ, Hay DW, Goldie RG. (1995) Receptors for endothelin-1 in asthmatic human peripheral lung. Br J Pharmacol 114:1–3.
    1. Ko C, Gieske MC, Al-Alem L, Hahn Y, Su W, Gong MC, Iglarz M, Koo Y. (2006) Endothelin-2 in ovarian follicle rupture. Endocrinology 147:1770–1779.
    1. Ko C, Meidan R, Bridges PJ. (2012) Why two endothelins and two receptors for ovulation and luteal regulation? Life Sci 91:501–506.
    1. Kobayashi T, Miyauchi T, Sakai S, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. (1999) Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol 276:H1197–H1206.
    1. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. (2012) Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 91:528–539.
    1. Kohan DE, Inscho EW, Wesson D, Pollock DM. (2011) Physiology of endothelin and the kidney. Compr Physiol 1:883–919.
    1. Kohan DE, Lambers Heerspink HJ, Coll B, Andress D, Brennan JJ, Kitzman DW, Correa-Rotter R, Makino H, Perkovic V, Hou FF, et al. (2015) Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clin J Am Soc Nephrol 10:1568–1574.
    1. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL. (2011a) Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22:763–772.
    1. Kohan DE, Rossi NF, Inscho EW, Pollock DM. (2011b) Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91:1–77.
    1. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, Valentine M, Barton D, Durham SK. (1995) Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 146:819–826.
    1. Krause SM, Walsh TF, Greenlee WJ, Ranaei R, Williams DL, Jr, Kivlighn SD. (1997) Renal protection by a dual ETA/ETB endothelin antagonist, L-754,142, after aortic cross-clamping in the dog. J Am Soc Nephrol 8:1061–1071.
    1. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V, Bosentan Hypertension Investigators (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338:784–790.
    1. Kuc RE, Carlebur M, Maguire JJ, Yang P, Long L, Toshner M, Morrell NW, Davenport AP. (2014) Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. Life Sci 118:391–396.
    1. Kuc RE, Karet FE, Davenport AP. (1995) Characterization of peptide and nonpeptide antagonists in human kidney. J Cardiovasc Pharmacol 26 (Suppl 3):S373–S375.
    1. Kuc RE, Maguire JJ, Davenport AP. (2006) Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ET(A) receptors in ET(B)-deficient mice. Exp Biol Med (Maywood) 231:741–745.
    1. Kurihara Y, Kurihara H, Maemura K, Kuwaki T, Kumada M, Yazaki Y. (1995a) Impaired development of the thyroid and thymus in endothelin-1 knockout mice. J Cardiovasc Pharmacol 26 (Suppl 3):S13–S16.
    1. Kurihara Y, Kurihara H, Oda H, Maemura K, Nagai R, Ishikawa T, Yazaki Y. (1995b) Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 96:293–300.
    1. Kurihara H, Kurihara Y, Nagai R, Yazaki Y. (1999) Endothelin and neural crest development. Cell Mol Biol (Noisy-le-grand) 45:639–651.
    1. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao WH, Kamada N, et al. (1994) Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368:703–710.
    1. Kurnik D, Haviv Y, Kochva E. (1999) A snake bite by the Burrowing Asp, Atractaspis engaddensis. Toxicon 37:223–227.
    1. Kuruppu S, Rajapakse NW, Dunstan RA, Smith AI. (2014) Nitric oxide inhibits the production of soluble endothelin converting enzyme-1. Mol Cell Biochem 396:49–54.
    1. Kuwaki T, Cao WH, Kurihara Y, Kurihara H, Ling GY, Onodera M, Ju KH, Yazaki Y, Kumada M. (1996) Impaired ventilatory responses to hypoxia and hypercapnia in mutant mice deficient in endothelin-1. Am J Physiol 270:R1279–1286.
    1. Kuwaki T, Ishii T, Ju K, Yanagisawa M, Fukuda Y. (2002) Blood pressure of endothelin-3 null (-/-) knockout mice and endothelin A receptor null (-/-) knockout mice under anaesthesia. Clin Sci (Lond) 103 (Suppl 48):48S–52S.
    1. Kuwaki T, Ling GY, Onodera M, Ishii T, Nakamura A, Ju KH, Cao WH, Kumada M, Kurihara H, Kurihara Y, Yazaki Y, Ohuchi T, Yanagisawa M, Fukuda Y. (1999) Endothelin in the central control of cardiovascular and respiratory functions. Clin Exp Pharmacol Physiol 26:989–994.
    1. Labruijere S, Compeer MG, van den Bogaerdt AJ, van den Brink AM, De Mey JG, Danser AH, Batenburg WW. (2013) Long-lasting physiological antagonism of calcitonin gene-related peptide towards endothelin-1 in rat mesenteric arteries and human coronary arteries. Eur J Pharmacol 720:303–309.
    1. Laffin LJ, Bakris GL. (2015) Endothelin antagonism and hypertension: an evolving target. Semin Nephrol 35:168–175.
    1. Lahav R, Suvà ML, Rimoldi D, Patterson PH, Stamenkovic I. (2004) Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res 64:8945–8953.
    1. Lakso M, Sauer B, Mosinger B, Jr, Lee EJ, Manning RW, Yu SH, Mulder KL, Westphal H. (1992) Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA 89:6232–6236.
    1. Larivière R, Lebel M. (2003) Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 81:607–621.
    1. Lebel M, Grose JH, Kingma I, Langlois S. (1994) Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy. Clin Exp Hypertens 16:565–575.
    1. Lee S, Lin M, Mele A, Cao Y, Farmar J, Russo D, Redman C. (1999) Proteolytic processing of big endothelin-3 by the kell blood group protein. Blood 94:1440–1450.
    1. Lemkens P, Nelissen J, Meens MJ, Fazzi GE, Janssen GJ, Debets JJ, Janssen BJ, Schiffers PM, De Mey JG. (2012a) Impaired flow-induced arterial remodeling in DOCA-salt hypertensive rats. Hypertens Res 35:1093–1101.
    1. Lemkens P, Nelissen J, Meens MJ, Janssen BJ, Schiffers PM, De Mey JG. (2012b) Dual neural endopeptidase/endothelin-converting [corrected] enzyme inhibition improves endothelial function in mesenteric resistance arteries of young spontaneously hypertensive rats. J Hypertens 30:1799–1808.
    1. Lenoir O, Milon M, Virsolvy A, Hénique C, Schmitt A, Massé JM, Kotelevtsev Y, Yanagisawa M, Webb DJ, Richard S, et al. (2014) Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol 25:1050–1062.
    1. Leonard MG, Briyal S, Gulati A. (2011) Endothelin B receptor agonist, IRL-1620, reduces neurological damage following permanent middle cerebral artery occlusion in rats. Brain Res 1420:48–58.
    1. Leonard MG, Briyal S, Gulati A. (2012) Endothelin B receptor agonist, IRL-1620, provides long-term neuroprotection in cerebral ischemia in rats. Brain Res 1464:14–23.
    1. Leonard MG, Gulati A. (2013) Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats. Brain Res 1528:28–41.
    1. Lerman A, Zeiher AM. (2005) Endothelial function: cardiac events. Circulation 111:363–368.
    1. Leslie SJ, Johnston N, Strachan FE, Bagnall A, Gray GA, Newby DE, Denvir MA, Webb DJ. (2004) Endothelin-1[1-31] is not elevated in men with chronic heart failure. J Cardiovasc Pharmacol 44 (Suppl 1):S96–S99.
    1. Leung JW, Ho MC, Lo AC, Chung SS, Chung SK. (2004) Endothelial cell-specific over-expression of endothelin-1 leads to more severe cerebral damage following transient middle cerebral artery occlusion. J Cardiovasc Pharmacol 44 (Suppl 1):S293–S300.
    1. Li JS, Larivière R, Schiffrin EL. (1994) Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 24:183–188.
    1. Li MW, Mian MO, Barhoumi T, Rehman A, Mann K, Paradis P, Schiffrin EL. (2013) Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 33:2306–2315.
    1. Liefeldt L, Bocker W, Schonfelder G, Zintz M, Paul M. (1995) Regulation of the endothelin system in transgenic rats expressing the human endothelin-2 gene. J Cardiovasc Pharmacol 26 Suppl 3:S32–33.
    1. Liefeldt L, Rylski B, Walcher F, Manhart J, Kron S, Rosenke YW, Paul M, Neumayer HH, Amann K, Peters H. (2010) Effects of transgenic endothelin-2 overexpression on diabetic cardiomyopathy in rats. Eur J Clin Invest 40:203–210.
    1. Liefeldt L, Schönfelder G, Böcker W, Hocher B, Talsness CE, Rettig R, Paul M. (1999) Transgenic rats expressing the human ET-2 gene: a model for the study of endothelin actions in vivo. J Mol Med (Berl) 77:565–574.
    1. Lin WW, Lee CY. (1992) Intestinal relaxation by endothelin isopeptides: involvement of Ca(2+)-activated K+ channels. Eur J Pharmacol 219:355–360.
    1. Ling L, Kuc RE, Maguire JJ, Davie NJ, Webb DJ, Gibbs P, Alexander GJ, Davenport AP. (2012) Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. Life Sci 91:716–722.
    1. Ling L, Maguire JJ, Davenport AP. (2013) Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. Br J Pharmacol 168:283–295.
    1. Ling GY, Cao WH, Onodera M, Ju KH, Kurihara H, Kurihara Y, Yazaki Y, Kumada M, Fukuda Y, Kuwaki T. (1998) Renal sympathetic nerve activity in mice: comparison between mice and rats and between normal and endothelin-1 deficient mice. Brain Res 808:238–249.
    1. Liu C, Chen J, Gao Y, Deng B, Liu K. (2013) Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2:CD004434.
    1. Liu Y, Yamada H, Ochi J. (1998) Immunocytochemical studies on endothelin in mast cells and macrophages in the rat gastrointestinal tract. Histochem Cell Biol 109:301–307.
    1. Lo AC, Chen AY, Hung VK, Yaw LP, Fung MK, Ho MC, Tsang MC, Chung SS, Chung SK. (2005) Endothelin-1 overexpression leads to further water accumulation and brain edema after middle cerebral artery occlusion via aquaporin 4 expression in astrocytic end-feet. J Cereb Blood Flow Metab 25:998–1011.
    1. Lorenzo MN, Khan RY, Wang Y, Tai SC, Chan GC, Cheung AH, Marsden PA. (2001) Human endothelin converting enzyme-2 (ECE2): characterization of mRNA species and chromosomal localization. Biochim Biophys Acta 1522:46–52.
    1. Love MP, Ferro CJ, Haynes WG, Plumpton C, Davenport AP, Webb DJ, McMurray JJ. (2000) Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res 47:166–172.
    1. Lucas GA, White LR, Juul R, Cappelen J, Aasly J, Edvinsson L. (1996) Relaxation of human temporal artery by endothelin ETB receptors. Peptides 17:1139–1144.
    1. Lüscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, Dietz R, Rousson V, Hürlimann D, Philipp S, et al. Heart Failure ET(A) Receptor Blockade Trial (2002) Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106:2666–2672.
    1. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. (2000) Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 101:142–147.
    1. Macdonald RL, Pluta RM, Zhang JH. (2007) Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 3:256–263.
    1. MacIntyre IM, Dhaun N, Lilitkarntakul P, Melville V, Goddard J, Webb DJ. (2010) Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. Hypertension 55:1406–1411.
    1. Maemura K, Kurihara H, Kurihara Y, Kuwaki T, Kumada M, Yazaki Y. (1995) Gene expression of endothelin isoforms and receptors in endothelin-1 knockout mice. J Cardiovasc Pharmacol 26 (Suppl 3):S17–S21.
    1. Maguire JJ, Davenport AP. (2012). Importance of sub-type selectivity for endothelin receptor antagonists in the human vasculature, in Translational Vascular Medicine: Pathogenesis, Diagnosis, and Treatment (Abraham D, Handler C, Dashwood M, Coghlan G. eds). pp 151–172, Springer; Heidelberg, Germany.
    1. Maguire JJ, Davenport AP. (2000) No alteration in vasoconstrictor endothelin-B-receptor density or function in human coronary artery disease. J Cardiovasc Pharmacol 36(5, Suppl 1)S380–S381.
    1. Maguire JJ, Davenport AP. (1995) ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol 115:191–197.
    1. Maguire JJ, Davenport AP. (1998) Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. British journal of pharmacology 125:238–240.
    1. Maguire JJ, Davenport AP. (1999) Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol 126:443–450.
    1. Maguire JJ, Davenport AP. (2014) Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol 171:5555–5572.
    1. Maguire JJ, Davenport AP. (2015) Endothelin receptors and their antagonists. Semin Nephrol 35:125–136.
    1. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. (2009) [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54:598–604.
    1. Maguire JJ, Kuc RE, Davenport AP. (1997) Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors. J Pharmacol Exp Ther 280:1102–1108.
    1. Maguire JJ, Kuc RE, Davenport AP. (2001) Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro. Br J Pharmacol 134:1360–1366.
    1. Maguire JJ, Kuc RE, O’Reilly G, Davenport AP. (1994) Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. Br J Pharmacol 113:49–54.
    1. Maguire JJ, Kuc RE, Rous BA, Davenport AP. (1996) Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments. Br J Pharmacol 118:335–342.
    1. Maguire J, Davenport AP. (2004) Alternative pathway to endothelin-converting enzyme for the synthesis of endothelin in human blood vessels. J Cardiovasc Pharmacol 44 (Suppl 1):S27–S29.
    1. Mai HQ, Zeng ZY, Feng KT, Ye YL, Zhang CQ, Liang WJ, Guo X, Mo HY, Hong MH. (2006) Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. Cancer Sci 97:1388–1395.
    1. Malek AM, Gibbons GH, Dzau VJ, Izumo S. (1993) Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet-derived growth factor B chain in vascular endothelium. J Clin Invest 92:2013–2021.
    1. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G, ASCEND Study Group (2010) Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21:527–535.
    1. Marciniak SJ, Plumpton C, Barker PJ, Huskisson NS, Davenport AP. (1992) Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmacol 5:175–182.
    1. Martin P, Ninio D, Krum H. (2002) Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension. Hypertension 39:821–824.
    1. Maschauer S, Michel K, Tripal P, Büther K, Kuwert T, Schober O, Kopka K, Riemann B, Prante O. (2013) Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography. Am J Nucl Med Mol Imaging 3:425–436.
    1. Masuda Y, Sugo T, Kikuchi T, Kawata A, Satoh M, Fujisawa Y, Itoh Y, Wakimasu M, Ohtaki T. (1996) Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors. J Pharmacol Exp Ther 279:675–685.
    1. Masuo Y, Ishikawa Y, Kozakai T, Uchide T, Komatsu Y, Saida K. (2003) Vasoactive intestinal contractor/endothelin-2 gene expression in the murine central nervous system. Biochem Biophys Res Commun 300:661–668.
    1. Matsumoto H, Suzuki N, Kitada C, Fujino M. (1994) Endothelin family peptides in human plasma and urine: their molecular forms and concentrations. Peptides 15:505–510.
    1. Matsumoto H, Suzuki N, Onda H, Fujino M. (1989) Abundance of endothelin-3 in rat intestine, pituitary gland and brain. Biochem Biophys Res Commun 164:74–80.
    1. Matsumura Y, Kuro T, Kobayashi Y, Konishi F, Takaoka M, Wessale JL, Opgenorth TJ, Gariepy CE, Yanagisawa M. (2000a) Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation 102:2765–2773.
    1. Matsumura Y, Kuro T, Kobayashi Y, Konishi F, Takaoka M, Wessale JL, Opgenorth TJ, Gariepy CE, Yanagisawa M. (2000b) Increased susceptibility to deoxycorticosterone acetate-salt-induced hypertension in endothelin-B-receptor-deficient rats. J Cardiovasc Pharmacol 36(5, Suppl 1)S86–S89.
    1. Matsumura Y, Kuro T, Konishi F, Takaoka M, Gariepy CE, Yanagisawa M. (2000c) Enhanced blood pressure sensitivity to DOCA-salt treatment in endothelin ET(B) receptor-deficient rats. Br J Pharmacol 129:1060–1062.
    1. Matsuo Y, Mihara Si, Ninomiya M, Fujimoto M. (2001) Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 32:2143–2148.
    1. Mattera GG, Eglezos A, Renzetti AR, Mizrahi J. (1993) Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan. Br J Pharmacol 110:331–337.
    1. Maurer M, Wedemeyer J, Metz M, Piliponsky AM, Weller K, Chatterjea D, Clouthier DE, Yanagisawa MM, Tsai M, Galli SJ. (2004) Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432:512–516.
    1. McCulloch KM, Docherty CC, Morecroft I, MacLean MR. (1996) EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 119:1125–1130.
    1. McKay KO, Black JL, Armour CL. (1991) The mechanism of action of endothelin in human lung. Br J Pharmacol 102:422–428.
    1. Meens MJ, Mattheij NJ, Nelissen J, Lemkens P, Compeer MG, Janssen BJ, De Mey JG. (2011) Calcitonin gene-related peptide terminates long-lasting vasopressor responses to endothelin 1 in vivo. Hypertension 58:99–106.
    1. Meidan R, Levy N. (2007) The ovarian endothelin network: an evolving story. Trends Endocrinol Metab 18:379–385.
    1. Metallinos DL, Bowling AT, Rine J. (1998) A missense mutation in the endothelin-B receptor gene is associated with Lethal White Foal Syndrome: an equine version of Hirschsprung disease. Mamm Genome 9:426–431.
    1. Meyer RC, Giddens MM, Schaefer SA, Hall RA. (2013) GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proc Natl Acad Sci USA 110:9529–9534.
    1. Miyagawa K, Emoto N. (2014) Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis 8:202–216.
    1. Miyamoto Y, Yoshimasa T, Arai H, Takaya K, Ogawa Y, Itoh H, Nakao K. (1996) Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts. Biochem J 313:795–801.
    1. Miyauchi Y, Sakai S, Maeda S, Shimojo N, Watanabe S, Honma S, Kuga K, Aonuma K, Miyauchi T. (2012) Increased plasma levels of big-endothelin-2 and big-endothelin-3 in patients with end-stage renal disease. Life Sci 91:729–732.
    1. Mizuguchi T, Nishiyama M, Moroi K, Tanaka H, Saito T, Masuda Y, Masaki T, de Wit D, Yanagisawa M, Kimura S. (1997) Analysis of two pharmacologically predicted endothelin B receptor subtypes by using the endothelin B receptor gene knockout mouse. Br J Pharmacol 120:1427–1430.
    1. Molenaar P, Kuc RE, Davenport AP. (1992) Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart. Br J Pharmacol 107:637–639.
    1. Molenaar P, O’Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA, Davenport AP. (1993) Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 72:526–538.
    1. Moorhouse RC, Webb DJ, Kluth DC, Dhaun N. (2013) Endothelin antagonism and its role in the treatment of hypertension. Curr Hypertens Rep 15:489–496.
    1. Moravec CS, Reynolds EE, Stewart RW, Bond M. (1989) Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun 159:14–18.
    1. Moreau P. (1998) Endothelin in hypertension: a role for receptor antagonists? Cardiovasc Res 39:534–542.
    1. Morita H, Kurihara H, Kurihara Y, Shindo T, Kuwaki T, Kumada M, Yazaki Y. (1998) Systemic and renal response to salt loading in endothelin-1 knockout mice. J Cardiovasc Pharmacol 31 Suppl 1:S557–560.
    1. Mortensen LH, Fink GD. (1992) Salt-dependency of endothelin-induced, chronic hypertension in conscious rats. Hypertension 19:549–554.
    1. Mortensen LH, Pawloski CM, Kanagy NL, Fink GD. (1990) Chronic hypertension produced by infusion of endothelin in rats. Hypertension 15:729–733.
    1. Morton AJ, Davenport AP. (1992) Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b. Brain Res 581:299–306.
    1. Motte S, McEntee K, Naeije R. (2006) Endothelin receptor antagonists. Pharmacol Ther 110:386–414.
    1. Mucke HA. (2009) Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas. IDrugs 12:366–375.
    1. Murakoshi N, Miyauchi T, Kakinuma Y, Ohuchi T, Goto K, Yanagisawa M, Yamaguchi I. (2002) Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. Circulation 106:1991–1998.
    1. Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT, et al. (2005) Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2′-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem 48:171–179.
    1. Mylona P, Cleland JG. (1999) Update of REACH-1 and MERIT-HF clinical trials in heart failure. Editorial Team. Eur J Heart Fail 1:197–200.
    1. Mzhavia N, Pan H, Che FY, Fricker LD, Devi LA. (2003) Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem 278:14704–14711.
    1. Nakamura A, Kuwaki T, Kuriyama T, Yanagisawa M, Fukuda Y. (2001) Normal ventilation and ventilatory responses to chemical stimuli in juvenile mutant mice deficient in endothelin-3. Respir Physiol 124:1–9.
    1. Nakano D, Pollock DM. (2009) Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension 53:324–330.
    1. Nakano D, Pollock JS, Pollock DM. (2008) Renal medullary ETB receptors produce diuresis and natriuresis via NOS1. Am J Physiol Renal Physiol 294:F1205–F1211.
    1. Nakov R, Pfarr E, Eberle S, Investigators H, HEAT Investigators (2002) Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 15:583–589.
    1. Nambi P, Pullen M, Spielman W. (1994) Species differences in the binding characteristics of [125I]IRL-1620, a potent agonist specific for endothelin-B receptors. J Pharmacol Exp Ther 268:202–207.
    1. Namer B, Hilliges M, Orstavik K, Schmidt R, Weidner C, Torebjörk E, Handwerker H, Schmelz M. (2008) Endothelin 1 activates and sensitizes human C-nociceptors. Pain 137:41–49.
    1. Nasser SA, El-Mas MM. (2014) Endothelin ETA receptor antagonism in cardiovascular disease. Eur J Pharmacol 737:210–213.
    1. Nelissen J, Lemkens P, Sann H, Bindl M, Bassissi F, Jasserand D, De Mey JG, Janssen BJ. (2012) Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme. Life Sci 91:587–592.
    1. Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M. (2012) Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118:5709–5718.
    1. Nelson RD, Stricklett P, Gustafson C, Stevens A, Ausiello D, Brown D, Kohan DE. (1998) Expression of an AQP2 Cre recombinase transgene in kidney and male reproductive system of transgenic mice. Am J Physiol 275:C216–C226.
    1. Newby DE, Strachan FE, Webb DJ. (2002) Abnormal endothelin B receptor vasomotor responses in patients with Hirschsprung’s disease. QJM 95:159–163.
    1. O’Callaghan K, Kuliopulos A, Covic L. (2012) Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem 287:12787–12796.
    1. O’Gorman S, Fox DT, Wahl GM. (1991) Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science 251:1351–1355.
    1. Ohkita M, Takaoka M, Shiota Y, Nojiri R, Matsumura Y. (2002) Nitric oxide inhibits endothelin-1 production through the suppression of nuclear factor kappa B. Clin Sci (Lond) 103 (Suppl 48):68S–71S.
    1. Ohkita M, Wang Y, Nguyen ND, Tsai YH, Williams SC, Wiseman RC, Killen PD, Li S, Yanagisawa M, Gariepy CE. (2005) Extrarenal ETB plays a significant role in controlling cardiovascular responses to high dietary sodium in rats. Hypertension 45:940–946.
    1. Ohkubo S, Ogi K, Hosoya M, Matsumoto H, Suzuki N, Kimura C, Ondo H, Fujino M. (1990) Specific expression of human endothelin-2 (ET-2) gene in a renal adenocarcinoma cell line. Molecular cloning of cDNA encoding the precursor of ET-2 and its characterization. FEBS Lett 274:136–140.
    1. Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Onodera M, Cao WH, Yanagisawa M, Kumada M. (1999) Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol 276:R1071–R1077.
    1. Oka M, Niwa Y, Mawatari K, Hiasa Y, Nakaya Y. (2014) A novel peptide of endothelin family, 31 amino-acid length endothelin in patients with acute myocardial infarction. J Med Invest 61:298–305.
    1. Okamoto Y, Ninomiya H, Masaki T. (1998) Posttranslational modifications of endothelin receptor type B. Trends Cardiovasc Med 8:327–329.
    1. Oliver JJ, Webb DJ. (2003) Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 23:554–566.
    1. Opitz CF, Ewert R, Kirch W, Pittrow D. (2008) Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 29:1936–1948.
    1. O’Reilly G, Charnock-Jones DS, Cameron IT, Smith SK, Davenport AP. (1993b) Endothelin-2 mRNA splice variants detected by RT-PCR in cultured human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 22 (Suppl 8):S18–S21.
    1. O’Reilly G, Charnock-Jones DS, Davenport AP, Cameron IT, Smith SK. (1992) Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle. J Clin Endocrinol Metab 75:1545–1549.
    1. O’Reilly G, Charnock-Jones DS, Morrison JJ, Cameron IT, Davenport AP, Smith SK. (1993a) Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution. Biochem Biophys Res Commun 193:834–840.
    1. Orry AJ, Wallace BA. (2000) Modeling and docking the endothelin G-protein-coupled receptor. Biophys J 79:3083–3094.
    1. Pacheco-Quinto J, Eckman EA. (2013) Endothelin-converting enzymes degrade intracellular β-amyloid produced within the endosomal/lysosomal pathway and autophagosomes. J Biol Chem 288:5606–5615.
    1. Palanisamy GS, Cheon YP, Kim J, Kannan A, Li Q, Sato M, Mantena SR, Sitruk-Ware RL, Bagchi MK, Bagchi IC. (2006) A novel pathway involving progesterone receptor, endothelin-2, and endothelin receptor B controls ovulation in mice. Mol Endocrinol 20:2784–2795.
    1. Palmer MJ. (2009) Endothelin receptor antagonists: status and learning 20 years on. Prog Med Chem 47:203–237.
    1. Parnot C, Le Moullec JM, Cousin MA, Guédin D, Corvol P, Pinet F. (1997) A live-cell assay for studying extracellular and intracellular endothelin-converting enzyme activity. Hypertension 30:837–844.
    1. Parvanova A, van der Meer IM, Iliev I, Perna A, Gaspari F, Trevisan R, Bossi A, Remuzzi G, Benigni A, Ruggenenti P, Daglutril in Diabetic Nephropathy Study Group (2013) Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1:19–27.
    1. Patel T, McKeage K. (2014) Macitentan: first global approval. Drugs 74:127–133.
    1. Patel TR, Galbraith S, Graham DI, Hallak H, Doherty AM, McCulloch J. (1996) Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J Cereb Blood Flow Metab 16:950–958.
    1. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, et al. NC-IUPHAR (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42:D1098–D1106.
    1. Pernow J, Shemyakin A, Böhm F. (2012) New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci 91:507–516.
    1. Perticone F, Maio R, Tripepi G, Zoccali C. (2004) Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 110:821–825.
    1. Peter MG, Davenport AP. (1995a) Delineation of endothelin receptors in human left ventricular smooth-muscle cells. J Cardiovasc Pharmacol 26 (Suppl 3):S355–S357.
    1. Peter MG, Davenport AP. (1995b) Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol 114:297–302.
    1. Peter MG, Davenport AP. (1996a) Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart. Br J Pharmacol 117:455–462.
    1. Peter MG, Davenport AP. (1996b) Upregulation of the endothelin ET(A) receptors in left ventricle from failing human hearts demonstrated using competition binding studies with FR139317. Br J Pharmacol 117:270.
    1. Peto H, Corder R, Janes RW, Wallace BA. (1996) A molecular model for human Big-Endothelin-1 (Big ET-1). FEBS Lett 394:191–195.
    1. Petrov T, Rafols JA. (2001) Acute alterations of endothelin-1 and iNOS expression and control of the brain microcirculation after head trauma. Neurol Res 23:139–143.
    1. Phelan M, Perrine SP, Brauer M, Faller DV. (1995) Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 96:1145–1151.
    1. Picard P, Smith PJ, Monge JC, Rouleau JL, Nguyen QT, Calderone A, Stewart DJ. (1998) Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure. J Cardiovasc Pharmacol 31 (Suppl 1):S294–S297.
    1. Pierre LN, Davenport AP. (1995) Autoradiographic study of endothelin receptors in human cerebral arteries. J Cardiovasc Pharmacol 26 (Suppl 3):S326–S328.
    1. Pierre LN, Davenport AP. (1998a) Endothelin receptor subtypes and their functional relevance in human small coronary arteries. Br J Pharmacol 124:499–506.
    1. Pierre LN, Davenport AP. (1998b) Relative contribution of endothelin A and endothelin B receptors to vasoconstriction in small arteries from human heart and brain. J Cardiovasc Pharmacol 31 (Suppl 1):S74–S76.
    1. Pierre LN, Davenport AP. (1999) Blockade and reversal of endothelin-induced constriction in pial arteries from human brain. Stroke 30:638–643.
    1. Pieske B, Beyermann B, Breu V, Löffler BM, Schlotthauer K, Maier LS, Schmidt-Schweda S, Just H, Hasenfuss G. (1999) Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 99:1802–1809.
    1. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, et al. (2007) International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 59:5–13.
    1. Piovezan AP, D’Orléans-Juste P, Souza GE, Rae GA. (2000) Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. Br J Pharmacol 129:961–968.
    1. Piovezan AP, D’Orléans-Juste P, Tonussi CR, Rae GA. (1998) Effects of endothelin-1 on capsaicin-induced nociception in mice. Eur J Pharmacol 351:15–22.
    1. Plumpton C, Champeney R, Ashby MJ, Kuc RE, Davenport AP. (1993) Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated. J Cardiovasc Pharmacol 22 (Suppl 8):S26–S28.
    1. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. (1996) The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 119:311–314.
    1. Plumpton C, Haynes WG, Webb DJ, Davenport AP. (1995) Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br J Pharmacol 116:1821–1828.
    1. Pollock DM, Pollock JS. (2001) Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 281:F144–F150.
    1. Pollock DM, Portik-Dobos V, Procter C, Gariepy CE, Yanagisawa M. (2000) Arterial pressure response to endothelin-1 and sarafotoxin 6c in rescued endothelin-B-deficient rats. J Cardiovasc Pharmacol 36(5, Suppl 1)S82–S85.
    1. Pönicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Böhm M, Zerkowski HR, Brodde OE. (1998) Endothelin receptors in the failing and nonfailing human heart. Circulation 97:744–751.
    1. Prinjha RK, Witherington J, Lee K. (2012) Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol Sci 33:146–153.
    1. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, et al. SERAPHIN Investigators (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–818.
    1. Purkiss JR, West D, Wilkes LC, Scott C, Yarrow P, Wilkinson GF, Boarder MR. (1994) Stimulation of phospholipase C in cultured microvascular endothelial cells from human frontal lobe by histamine, endothelin and purinoceptor agonists. Br J Pharmacol 111:1041–1046.
    1. Quaschning T, Koçak S, Bauer C, Neumayer HH, Galle J, Hocher B. (2003) Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. Nephrol Dial Transplant 18:479–483.
    1. Quaschning T, Rebhan B, Wunderlich C, Wanner C, Richter CM, Pfab T, Bauer C, Kraemer-Guth A, Galle J, Yanagisawa M, et al. (2005) Endothelin B receptor-deficient mice develop endothelial dysfunction independently of salt loading. J Hypertens 23:979–985.
    1. Quaschning T, Voss F, Herzfeld S, Relle K, Kalk P, Godes M, Pfab T, Kraemer-Guth A, Bonz AW, Theuring F, Galle J, Hocher B. (2008) Lack of iNOS impairs endothelial function in endothelin-1 transgenic mice. Kidney Blood Press Res 31:127–134.
    1. Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, Bauer C, Theilig F, Bachmann S, Kraemer-Guth A, Wanner C, Theuring F, Galle J, Hocher B. (2007) Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol 18:730–740.
    1. Rafnsson A, Shemyakin A, Pernow J. (2014) Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease. Life Sci 118:435–439.
    1. Rajeshkumar NV, Rai A, Gulati A. (2005) Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 94:237–247.
    1. Rapoport RM. (2014) Nitric oxide inhibition of endothelin-1 release in the vasculature: in vivo relevance of in vitro findings. Hypertension 64:908–914.
    1. Rautureau Y, Schiffrin EL. (2012) Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens 21:128–136.
    1. Regard JB, Sato IT, Coughlin SR. (2008) Anatomical profiling of G protein-coupled receptor expression. Cell 135:561–571.
    1. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, Lennon R, Rihal C, Lerman LO, Lerman A. (2010) Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 122:958–966.
    1. Reynolds EE, Hwang O, Flynn MA, Welch KM, Cody WL, Steinbaugh B, He JX, Chung FZ, Doherty AM. (1995) Pharmacological differences between rat and human endothelin B receptors. Biochemi Biophys Res Comm 209:506–512.
    1. Rice J, Doggett B, Sweetser DA, Yanagisawa H, Yanagisawa M, Kapur RP. (2000) Transgenic rescue of aganglionosis and piebaldism in lethal spotted mice. Dev Dyn 217:120–132.
    1. Rivera A, Rotter MA, Brugnara C. (1999) Endothelins activate Ca(2+)-gated K(+) channels via endothelin B receptors in CD-1 mouse erythrocytes. Am J Physiol 277:C746–C754.
    1. Rockey DC, Weisiger RA. (1996) Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 24:233–240.
    1. Rohmeiss P, Birck R, Braun C, Munter K, van der Woude FJ, Kirchengast M. (1998) Pharmacology of the endothelin(A) receptor antagonist: LU 135252. Cardiovasc Drug Rev 16:391–412.
    1. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A. (2009) Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106:2806–2811.
    1. Rosanò L, Spinella F, Bagnato A. (2013a) Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 13:637–651.
    1. Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A. (2013b) β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene 32:5066–5077.
    1. Rossi GP, Albertin G, Franchin E, Sacchetto A, Cesari M, Palù G, Pessina AC. (1995) Expression of the endothelin-converting enzyme gene in human tissues. Biochem Biophys Res Commun 211:249–253.
    1. Roubert P, Gillard V, Plas P, Chabrier PE, Braquet P. (1991) Binding characteristics of endothelin isoforms (ET-1, ET-2, and ET-3) in vascular smooth muscle cells. J Cardiovasc Pharmacol 17 (Suppl 7):S104–S108.
    1. Roux S, Qiu C, Sprecher U, Osterwalder R, Clozel JP. (1999) Protective effects of endothelin receptor antagonists in dogs with aortic cross-clamping. J Cardiovasc Pharmacol 34:199–205.
    1. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, Hoeffken G. (2001) Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120:1562–1569.
    1. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903.
    1. Ruest LB, Kedzierski R, Yanagisawa M, Clouthier DE. (2005) Deletion of the endothelin-A receptor gene within the developing mandible. Cell Tissue Res 319:447–453.
    1. Ruest LB, Xiang X, Lim KC, Levi G, Clouthier DE. (2004) Endothelin-A receptor-dependent and -independent signaling pathways in establishing mandibular identity. Development 131:4413–4423.
    1. Russell FD, Davenport AP. (1995) Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139. J Cardiovasc Pharmacol 26 (Suppl 3):S346–S347.
    1. Russell FD, Davenport AP. (1996) Characterization of the binding of endothelin ETB selective ligands in human and rat heart. Br J Pharmacol 119:631–636.
    1. Russell FD, Davenport AP. (1999a) Secretory pathways in endothelin synthesis. Br J Pharmacol 126:391–398.
    1. Russell FD, Davenport AP. (1999b) Evidence for intracellular endothelin-converting enzyme-2 expression in cultured human vascular endothelial cells. Circ Res 84:891–896.
    1. Russell FD, Coppell AL, Davenport AP. (1998) In vitro enzymatic processing of radiolabelled big ET-1 in human kidney. Biochem Pharmacol 55:697–701.
    1. Russell FD, Skepper JN, Davenport AP. (1997) Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography. J Cardiovasc Pharmacol 29:820–826.
    1. Saeki T, Ihara M, Fukuroda T, Yamagiwa M, Yano M. (1991) [Ala1,3,11,15]endothelin-1 analogs with ETB agonistic activity. Biochem Biophys Res Commun 179:286–292.
    1. Saida K, Hashimoto M, Mitsui Y, Ishida N, Uchide T. (2000) The prepro vasoactive intestinal contractor (VIC)/endothelin-2 gene (EDN2): structure, evolution, production, and embryonic expression. Genomics 64:51–61.
    1. Saida K, Kometani N, Uchide T, Mitsui Y. (2002) Sequence analysis and expression of the mouse full-length vasoactive intestinal contractor/endothelin-2 gene (EDN2): comparison with the endothelin-1 gene (EDN1). Clin Sci (Lond) 103 (Suppl 48):84S–89S.
    1. Saida K, Mitsui Y, Ishida N. (1989) A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. J Biol Chem 264:14613–14616.
    1. Saito Y, Kazuwa N, Shirakami G, Mukoyama M, Arai H, Hosoda K, Suga S, Ogawa Y, Imura H. (1991) Endothelin in patients with chronic renal failure. J Cardiovasc Pharmacol 17 (Suppl 7):S437–S439.
    1. Saito Y, Nakao K, Mukoyama M, Imura H. (1990) Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 322:205.
    1. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. (1996) Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93:1214–1222.
    1. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. (1990) Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348:732–735.
    1. Sandoval YH, Atef ME, Levesque LO, Li Y, Anand-Srivastava MB. (2014) Endothelin-1 signaling in vascular physiology and pathophysiology. Curr Vasc Pharmacol 12:202–214.
    1. Sato T, Kurihara Y, Asai R, Kawamura Y, Tonami K, Uchijima Y, Heude E, Ekker M, Levi G, Kurihara H. (2008) An endothelin-1 switch specifies maxillomandibular identity. Proc Natl Acad Sci USA 105:18806–18811.
    1. Schiffrin EL. (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14:83S–89S.
    1. Schiffrin EL. (2005) Vascular endothelin in hypertension. Vascul Pharmacol 43:19–29.
    1. Schiffrin EL, Thibault G. (1991) Plasma endothelin in human essential hypertension. Am J Hypertens 4:303–308.
    1. Schinelli S. (2006) Pharmacology and physiopathology of the brain endothelin system: an overview. Curr Med Chem 13:627–638.
    1. Schlenz AM, McClellan CB, Mark TR, McKelvy AD, Puffer E, Roberts CW, Sweitzer SM, Schatz JC. (2012) Sensitization to acute procedural pain in pediatric sickle cell disease: modulation by painful vaso-occlusive episodes, age, and endothelin-1. J Pain 13:656–665.
    1. Schneider MP, Ge Y, Pollock DM, Pollock JS, Kohan DE. (2008) Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension 51:1605–1610.
    1. Schoeffter P, Randriantsoa A. (1993) Differences between endothelin receptors mediating contraction of guinea-pig aorta and pig coronary artery. Eur J Pharmacol 249:199–206.
    1. Schweizer A, Valdenaire O, Nelböck P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG, Löffler BM. (1997) Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J 328:871–877.
    1. Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP. (2012) The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci 91:743–748.
    1. Semaan W, Desbiens L, Houde M, Labonté J, Gagnon H, Yamamoto D, Takai S, Laidlaw T, Bkaily G, Schwertani A, et al. (2015) Chymase inhibitor-sensitive synthesis of endothelin-1 (1-31) by recombinant mouse mast cell protease 4 and human chymase. Biochem Pharmacol 94:91–100.
    1. Sharkovska Y, Kalk P, von Websky K, Relle K, Pfab T, Alter M, Fischer Y, Hocher B. (2011) Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab 57:507–515.
    1. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. (2000) Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 93:992–997.
    1. Shiba R, Sakurai T, Yamada G, Morimoto H, Saito A, Masaki T, Goto K. (1992) Cloning and expression of rat preproendothelin-3 cDNA. Biochemi Bioph Res Comm 186:588–594.
    1. Shimada K, Takahashi M, Tanzawa K. (1994) Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 269:18275–18278.
    1. Shindo T, Kurihara H, Maemura K, Kurihara Y, Ueda O, Suzuki H, Kuwaki T, Ju KH, Wang Y, Ebihara A, et al. (2002) Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. J Mol Med (Berl) 80:105–116.
    1. Shinmi O, Yorimitsu K, Moroi K, Nishiyama M, Sugita Y, Saito T, Inagaki Y, Masaki T, Kimura S. (1993) Endothelin-2-converting enzyme from human renal adenocarcinoma cells is a phosphoramidon-sensitive, membrane-bound metalloprotease. J Cardiovasc Pharmacol 22 (Suppl 8):S61–S64.
    1. Shohet RV, Kisanuki YY, Zhao XS, Siddiquee Z, Franco F, Yanagisawa M. (2004) Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc Natl Acad Sci USA 101:2088–2093.
    1. Shukla AK, Xiao K, Lefkowitz RJ. (2011) Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 36:457–469.
    1. Shyamala V, Moulthrop TH, Stratton-Thomas J, Tekamp-Olson P. (1994) Two distinct human endothelin B receptors generated by alternative splicing from a single gene. Cell Mol Biol Res 40:285–296.
    1. Sidharta PN, Krähenbühl S, Dingemanse J. (2015) Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol 11:437–449.
    1. Sidharta PN, Lindegger N, Ulč I, Dingemanse J. (2014) Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol 54:291–300.
    1. Sidharta PN, van Giersbergen PL, Dingemanse J. (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol 53:1131–1138.
    1. Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. (2011) Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 67:977–984.
    1. Simeone SM, Li MW, Paradis P, Schiffrin EL. (2011) Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics 43:148–160.
    1. Skolovsky M, Galron R, Kloog Y, Bdolah A, Indig FE, Blumberg S, Fleminger G. (1990) Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: possible physiological significance. Proc Natl Acad Sci USA 87:4702–4706.
    1. Skovsted GF, Kruse LS, Larsen R, Pedersen AF, Trautner S, Sheykhzade M, Edvinsson L. (2014) Heart ischaemia-reperfusion induces local up-regulation of vasoconstrictor endothelin ETB receptors in rat coronary arteries downstream of occlusion. Br J Pharmacol 171:2726–2738.
    1. Smith TP, Haymond T, Smith SN, Sweitzer SM. (2014) Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. J Pain Res 7:531–545.
    1. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. (1985) Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 317:230–234.
    1. Smolander J, Vogt B, Maillard M, Zweiacker C, Littke T, Hengelage T, Burnier M. (2009) Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin Pharmacol Ther 85:628–634.
    1. Smollich M, Götte M, Yip GW, Yong ES, Kersting C, Fischgräbe J, Radke I, Kiesel L, Wülfing P. (2007) On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat 106:361–369.
    1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, et al. NC-IUPHAR (2015) The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res gkv1037.
    1. Spatz M, Kawai N, Merkel N, Bembry J, McCarron RM. (1997) Functional properties of cultured endothelial cells derived from large microvessels of human brain. Am J Physiol 272:C231–C239.
    1. Speed JS, Pollock DM. (2013) Endothelin, kidney disease, and hypertension. Hypertension 61:1142–1145.
    1. Speed JS, D’Angelo G, Wach PA, Sullivan JC, Pollock JS, Pollock DM. (2015) High salt diet increases the pressor response to stress in female, but not male ETB-receptor-deficient rats. Physiol Rep 3:3.
    1. Spence R, Mandagere A, Dufton C, Venitz J. (2008) Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol 48:1451–1459.
    1. Spinella F, Caprara V, Cianfrocca R, Rosanò L, Di Castro V, Garrafa E, Natali PG, Bagnato A. (2014) The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis 35:840–848.
    1. Spinella F, Caprara V, Garrafa E, Di Castro V, Rosanò L, Natali PG, Bagnato A. (2010) Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells. Can J Physiol Pharmacol 88:782–787.
    1. Spratt JCS, Goddard J, Patel N, Strachan FE, Rankin AJ, Webb DJ. (2001) Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 134:648–654.
    1. Stanimirovic DB, Yamamoto T, Uematsu S, Spatz M. (1994) Endothelin-1 receptor binding and cellular signal transduction in cultured human brain endothelial cells. J Neurochem 62:592–601.
    1. Stannard C, Lehenkari P, Godovac-Zimmermann J. (2003b) Functional diversity of endothelin pathways in human lung fibroblasts may be based on structural diversity of the endothelin receptors. Biochemistry 42:13909–13918.
    1. Stannard C, Soskic V, Godovac-Zimmermann J. (2003a) Rapid changes in the phosphoproteome show diverse cellular responses following stimulation of human lung fibroblasts with endothelin-1. Biochemistry 42:13919–13928.
    1. Sternberg N, Hamilton D. (1981) Bacteriophage P1 site-specific recombination. I. Recombination between loxP sites. J Mol Biol 150:467–486.
    1. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. (1992) Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 85:510–517.
    1. Stewart DJ, Levy RD, Cernacek P, Langleben D. (1991a) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114:464–469.
    1. Stewart DJ, Kubac G, Costello KB, Cernacek P. (1991b) Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 18:38–43.
    1. Stow LR, Jacobs ME, Wingo CS, Cain BD. (2011) Endothelin-1 gene regulation. FASEB J 25:16–28.
    1. Strachan FE, Crockett TR, Mills NL, Gray GA, Webb DJ. (2000) Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin s6c, in human resistance and capacitance vessels in vivo. Br J Clin Pharmacol 50:27–30.
    1. Strachan FE, Haynes WG, Webb DJ. (1995) Endothelium-dependent modulation of venoconstriction to sarafotoxin S6c in human veins in vivo. J Cardiovasc Pharmacol 26 (Suppl 3):S180–S182.
    1. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ. (1999) Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33:581–585.
    1. Strait KA, Stricklett PK, Kohan DE. (2007) Altered collecting duct adenylyl cyclase content in collecting duct endothelin-1 knockout mice. BMC Nephrol 8:8.
    1. Stricklett PK, Hughes AK, Kohan DE. (2006) Endothelin-1 stimulates NO production and inhibits cAMP accumulation in rat inner medullary collecting duct through independent pathways. Am J Physiol Renal Physiol 290:F1315–F1319.
    1. Stuart D, Chapman M, Rees S, Woodward S, Kohan DE. (2013) Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention. J Pharmacol Exp Ther 346:182–189.
    1. Stuart D, Rees S, Woodward SK, Koesters R, Strait KA, Kohan DE. (2012) Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrol 13:166.
    1. Sullivan JC, Pollock JS, Pollock DM. (2006) Superoxide-dependent hypertension in male and female endothelin B receptor-deficient rats. Exp Biol Med (Maywood) 231:818–823.
    1. Suzuki N, Matsumoto H, Miyauchi T, Kitada C, Tsuda M, Goto K, Masaki T, Fujino M. (1991) Sandwich-enzyme immunoassays for endothelin family peptides. J Cardiovasc Pharmacol 17 (Suppl 7):S420–S422.
    1. Tabrizchi R. (2003) SLV-306. Solvay. Curr Opin Investig Drugs 4:329–332.
    1. Takahashi K, Ghatei MA, Jones PM, Murphy JK, Lam HC, O’Halloran DJ, Bloom SR. (1991) Endothelin in human brain and pituitary gland: comparison with rat. J Cardiovasc Pharmacol 17 (Suppl 7):S101–S103.
    1. Takahashi M, Matsushita Y, Iijima Y, Tanzawa K. (1993) Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem 268:21394–21398.
    1. Takahashi T, Barnes PJ, Kawikova I, Yacoub MH, Warner TD, Belvisi MG. (1997) Contraction of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan. Eur J Pharmacol 324:219–222.
    1. Takai M, Umemura I, Yamasaki K, Watakabe T, Fujitani Y, Oda K, Urade Y, Inui T, Yamamura T, Okada T. (1992) A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor. Biochem Biophys Res Commun 184:953–959.
    1. Takasaki C, Tamiya N, Bdolah A, Wollberg Z, Kochva E. (1988) Sarafotoxins S6: several isotoxins from Atractaspis engaddensis (burrowing asp) venom that affect the heart. Toxicon 26:543–548.
    1. Takizawa S, Uchide T, Adur J, Kozakai T, Kotake-Nara E, Quan J, Saida K. (2005) Differential expression of endothelin-2 along the mouse intestinal tract. J Mol Endocrinol 35:201–209.
    1. Talbodec A, Berkane N, Blandin V, Breittmayer JP, Ferrari E, Frelin C, Vigne P. (2000) Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol Pharmacol 57:797–804.
    1. Tanaka H, Moroi K, Iwai J, Takahashi H, Ohnuma N, Hori S, Takimoto M, Nishiyama M, Masaki T, Yanagisawa M, et al. (1998) Novel mutations of the endothelin B receptor gene in patients with Hirschsprung’s disease and their characterization. J Biol Chem 273:11378–11383.
    1. Tanaka T, Ogawa T, Matsuda Y. (1995) Species difference in the binding characteristics of RES-701-1: potent endothelin ETB receptor-selective antagonist. Biochem Biophys Res Commun 209:712–716.
    1. Tanese K, Fukuma M, Ishiko A, Sakamoto M. (2010) Endothelin-2 is upregulated in basal cell carcinoma under control of Hedgehog signaling pathway. Biochem Biophys Res Commun 391:486–491.
    1. Tanoue A, Koshimizu TA, Tsuchiya M, Ishii K, Osawa M, Saeki M, Tsujimoto G. (2002) Two novel transcripts for human endothelin B receptor produced by RNA editing/alternative splicing from a single gene. J Biol Chem 277:33205–33212.
    1. Tao K, Wu C, Wu K, Li W, Han G, Shuai X, Wang G. (2012) Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer. Med Oncol 29:107–112.
    1. Taylor TA, Gariepy CE, Pollock DM, Pollock JS. (2003) Gender differences in ET and NOS systems in ETB receptor-deficient rats: effect of a high salt diet. Hypertension 41:657–662.
    1. Teerlink JR. (2002) Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail 8:124–127.
    1. Télémaque S, D’Orléans-Juste P. (1991) Presence of a phosphoramidon-sensitive endothelin-converting enzyme which converts big-endothelin-1, but not big-endothelin-3, in the rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol 344:505–507.
    1. Teoh JP, Park KM, Wang Y, Hu Q, Kim S, Wu G, Huang S, Maihle N, Kim IM. (2014) Endothelin-1/endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis. Cell Signal 26:2885–2895.
    1. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC. (1999) Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 99:2185–2191.
    1. Theuring F, Thöne-Reinecke C, Vogler H, Schmager F, Rohmeiss P, Slowinski T, Neumayer HH, Hocher B. (1998) Pathophysiology in endothelin-1 transgenic mice. J Cardiovasc Pharmacol 31 (Suppl 1):S489–S491.
    1. Thomas KR, Capecchi MR. (1987) Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51:503–512.
    1. Thöne-Reinke C, Simon K, Richter CM, Godes M, Neumayer HH, Thormählen D, Hocher B. (2004) Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol 44 (Suppl 1):S76–S79.
    1. Thorin E, Nguyen TD, Bouthillier A. (1998) Control of vascular tone by endogenous endothelin-1 in human pial arteries. Stroke 29:175–180.
    1. Treiber A, Äänismaa P, de Kanter R, Delahaye S, Treher M, Hess P, Sidharta P. (2014) Macitentan does not interfere with hepatic bile salt transport. J Pharmacol Exp Ther 350:130–143.
    1. Tsang MC, Lo AC, Cheung PT, Chung SS, Chung SK. (2001) Perinatal hypoxia-/ischemia-induced endothelin-1 mRNA in astrocyte-like and endothelial cells. Neuroreport 12:2265–2270.
    1. Turner AJ, Murphy LJ. (1996) Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol 51:91–102.
    1. Turner AJ, Tanzawa K. (1997) Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 11:355–364.
    1. Uchide T, Masuda H, Lee YS, Makiyama Y, Mitsui Y, Saida K. (2000) Fluctuating gene expression and localized cellular distribution of vasoactive intestinal contractor (VIC) in mouse uterus. J Histochem Cytochem 48:699–707.
    1. Uchide T, Masuda H, Mitsui Y, Saida K. (1999) Gene expression of vasoactive intestinal contractor/endothelin-2 in ovary, uterus and embryo: comprehensive gene expression profiles of the endothelin ligand-receptor system revealed by semi-quantitative reverse transcription-polymerase chain reaction analysis in adult mouse tissues and during late embryonic development. J Mol Endocrinol 22:161–171.
    1. Unger EF, Thompson AM, Blank MJ, Temple R. (2010) Erythropoiesis-stimulating agents--time for a reevaluation. N Engl J Med 362:189–192.
    1. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. (2010) Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11:636–646.
    1. Vachiéry JL, Davenport A. (2009) The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses. Eur Respir Rev 18:260–271.
    1. Valdenaire O, Lepailleur-Enouf D, Egidy G, Thouard A, Barret A, Vranckx R, Tougard C, Michel JB. (1999) A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. Eur J Biochem 264:341–349.
    1. van der Lee MM, Verkaar F, Wat JW, van Offenbeek J, Timmerman M, Voorneveld L, van Lith LH, Zaman GJ. (2013) β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor. Cell Signal 25:527–538.
    1. Vatter H, Seifert V. (2006) Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev 24:63–76.
    1. Vatter H, Zimmermann M, Weyrauch E, Lange BN, Setzer M, Raabe A, Seifert V. (2003) Cerebrovascular characterization of the novel nonpeptide endothelin-A receptor antagonist LU 208075. Clin Neuropharmacol 26:73–83.
    1. Vergouwen MD, Algra A, Rinkel GJ. (2012) Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 43:2671–2676.
    1. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. (1998) Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752–756.
    1. Vierhapper H, Wagner O, Nowotny P, Waldhäusl W. (1990) Effect of endothelin-1 in man. Circulation 81:1415–1418.
    1. Vignon-Zellweger N, Relle K, Kienlen E, Alter M, Seider P, Sharkovska J, Heiden S, Kalk P, Schwab K, Albrecht-Küpper B, et al. (2011) Endothelin-1 overexpression restores diastolic function in eNOS knockout mice. J Hypertens 29:961–970.
    1. Vignon-Zellweger N, Relle K, Rahnenführer J, Schwab K, Hocher B, Theuring F. (2014) Endothelin-1 overexpression and endothelial nitric oxide synthase knock-out induce different pathological responses in the heart of male and female mice. Life Sci 118:219–225.
    1. Vikman P, Beg S, Khurana TS, Hansen-Schwartz J, Edvinsson L. (2006) Gene expression and molecular changes in cerebral arteries following subarachnoid hemorrhage in the rat. J Neurosurg 105:438–444.
    1. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW. (2010) Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572–579.
    1. Vizza CD, Fedele F, Pezzuto B, Rubin LJ. (2012) Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf 11:1003–1011.
    1. Volpe M, Cosentino F. (2000) Abnormalities of endothelial function in the pathogenesis of stroke: the importance of endothelin. J Cardiovasc Pharmacol 35(4, Suppl 2)S45–S48.
    1. Vuurmans TJ, Boer P, Koomans HA. (2003) Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension 41:1253–1258.
    1. Wallace BA, Janes RW. (1995) The crystal structure of human endothelin-1 and how it relates to receptor binding. J Cardiovasc Pharmacol 26 (Suppl 3):S250–S253.
    1. Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, Lefkowitz RJ. (2009) β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 119:1312–1321.
    1. Wang R, Lohr CV, Fischer K, Dashwood WM, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, Dashwood RH. (2013) Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer. Int J Cancer 132:1004–1012.
    1. Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D’Agostino RB, Levy D, Vasan RS. (2005) Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 111:1370–1376.
    1. Warner TD, Allcock GH, Vane JR. (1994) Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol 112:207–213.
    1. Watakabe T, Urade Y, Takai M, Umemura I, Okada T. (1992) A reversible radioligand specific for the ETB receptor: [125I]Tyr13-Suc-[Glu9,Ala11,15]-endothelin-1(8- 21), [125I]IRL 1620. Biochem Biophys Res Commun 185:867–873.
    1. Watanabe Y, Naruse M, Monzen C, Naruse K, Ohsumi K, Horiuchi J, Yoshihara I, Kato Y, Nakamura N, Kato M, et al. (1991) Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol 17 (Suppl 7):S503–S505.
    1. Watts SW, Thakali K, Smark C, Rondelli C, Fink GD. (2007) Big ET-1 processing into vasoactive peptides in arteries and veins. Vascul Pharmacol 47:302–312.
    1. Webb DJ. (1995) Endogenous endothelin generation maintains vascular tone in humans. J Hum Hypertens 9:459–463.
    1. Webb DJ. (2010) DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension 56:806–807.
    1. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, van Marle S, Viischer HW, Jonkman JH. (1999) Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 39:703–714.
    1. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, Jonkman JH, Jones CR. (1996) Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124–137.
    1. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374:1423–1431.
    1. Weitzberg E, Hemsen A, Lundberg JM, Ahlborg G. (1995) ET-3 is extracted by and induces potent vasoconstriction in human splanchnic and renal vasculatures. J Appl Physiol (1985) 79:1255–1259.
    1. Welch AK, Jacobs ME, Wingo CS, Cain BD. (2013) Early progress in epigenetic regulation of endothelin pathway genes. Br J Pharmacol 168:327–334.
    1. Weng X, Yu L, Liang P, Li L, Dai X, Zhou B, Wu X, Xu H, Fang M, Chen Q, et al. (2015) A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 82:48–58.
    1. Wengenmayer C, Krikov M, Mueller S, Lucht K, Villringer A, Hocher B, Unger T, Thoene-Reineke C. (2011) Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival. Neurol Res 33:201–207.
    1. Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A, SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators (2009) Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20:655–664.
    1. Wenzel RR, Zbinden S, Noll G, Meier B, Lüscher TF. (1998) Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide. Br J Clin Pharmacol 45:441–446.
    1. Wessale JL, Adler AL, Novosad EI, Calzadilla SV, Dayton BD, Marsh KC, Winn M, Jae HS, von Geldern TW, Opgenorth TJ, et al. (2002) Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci (Lond) 103 (Suppl 48):112S–117S.
    1. Westby CM, Weil BR, Greiner JJ, Stauffer BL, DeSouza CA. (2011) Endothelin-1 vasoconstriction and the age-related decline in endothelium-dependent vasodilatation in men. Clin Sci (Lond) 120:485–491.
    1. Whyteside AR, Turner AJ, Lambert DW. (2014) Endothelin-converting enzyme-1 (ECE-1) is post-transcriptionally regulated by alternative polyadenylation. PLoS One 9:e83260.
    1. Wiley KE, Davenport AP. (2000) Novel nitric oxide donors reverse endothelin-1-mediated constriction in human blood vessels. J Cardiovasc Pharmacol 36(5, Suppl 1)S151–S152.
    1. Wiley KE, Davenport AP. (2001a) Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br J Pharmacol 133:568–574.
    1. Wiley KE, Davenport AP. (2001b) Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system. Br J Pharmacol 132:213–220.
    1. Wiley KE, Davenport AP. (2002) Comparison of the effects of atherosclerosis and nitrate therapy on responses to nitric oxide and endothelin-1 in human arteries in vitro. Clin Sci (Lond) 103 (Suppl 48):124S–127S.
    1. Wilhelm SM, Simonson MS, Robinson AV, Stowe NT, Schulak JA. (1999) Endothelin up-regulation and localization following renal ischemia andpodocyte. Kidney Int 55:1011-1018.
    1. Williams DL, Jr, Jones KL, Pettibone DJ, Lis EV, Clineschmidt BV. (1991) Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun 175:556–561.
    1. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, Weber C, Macdonald PS. (2000) Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 102:411–418.
    1. Wisler JW, Xiao K, Thomsen AR, Lefkowitz RJ. (2014) Recent developments in biased agonism. Curr Opin Cell Biol 27:18–24.
    1. Wright CE, Fozard JR. (1988) Regional vasodilation is a prominent feature of the haemodynamic response to endothelin in anaesthetized, spontaneously hypertensive rats. Eur J Pharmacol 155:201–203.
    1. Wu C, Chan MF, Stavros F, Raju B, Okun I, Mong S, Keller KM, Brock T, Kogan TP, Dixon RA. (1997) Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 40:1690–1697.
    1. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. (1994) ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78:473–485.
    1. Yamaga S, Tsutsumi K, Niwa M, Kitagawa N, Anda T, Himeno A, Khalid H, Taniyama K, Shibata S. (1995) Endothelin receptor in microvessels isolated from human meningiomas: quantification with radioluminography. Cell Mol Neurobiol 15:327–340.
    1. Yamamoto T, Shimoyama N, Asano H, Mizuguchi T. (1994) Analysis of the role of endothelin-A and endothelin-B receptors on nociceptive information transmission in the spinal cord with FR139317, an endothelin-A receptor antagonist, and sarafotoxin S6c, an endothelin-B receptor agonist. J Pharmacol Exp Ther 271:156–163.
    1. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda Si, Clouthier DE, Yanagisawa M. (2000) Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 105:1373–1382.
    1. Yanagisawa H, Hammer RE, Richardson JA, Williams SC, Clouthier DE, Yanagisawa M. (1998a) Role of Endothelin-1/Endothelin-A receptor-mediated signaling pathway in the aortic arch patterning in mice. J Clin Invest 102:22–33.
    1. Yanagisawa H, Yanagisawa M, Kapur RP, Richardson JA, Williams SC, Clouthier DE, de Wit D, Emoto N, Hammer RE. (1998b) Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125:825–836.
    1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415.
    1. Yang GY, Betz AL. (1994) Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. Stroke 25:1658–1664; discussion 1664-1655.
    1. Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, Stewart DJ. (2004) Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109:255–261.
    1. Yen H, Zhang Y, Penfold S, Rollins BJ. (1997) MCP-1-mediated chemotaxis requires activation of non-overlapping signal transduction pathways. J Leukoc Biol 61:529–532.
    1. Yeung PK, Shen J, Chung SS, Chung SK. (2013) Targeted over-expression of endothelin-1 in astrocytes leads to more severe brain damage and vasospasm after subarachnoid hemorrhage. BMC Neurosci 14:131.
    1. Yorimitsu K, Moroi K, Inagaki N, Saito T, Masuda Y, Masaki T, Seino S, Kimura S. (1995) Cloning and sequencing of a human endothelin converting enzyme in renal adenocarcinoma (ACHN) cells producing endothelin-2. Biochem Biophys Res Commun 208:721–727.
    1. Yorimitsu K, Shinmi O, Nishiyama M, Moroi K, Sugita Y, Saito T, Inagaki Y, Masaki T, Kimura S. (1992) Effect of phosphoramidon on big endothelin-2 conversion into endothelin-2 in human renal adenocarcinoma (ACHN) cells. Analysis of endothelin-2 biosynthetic pathway. FEBS Lett 314:395–398.
    1. Yoshinaga M, Chijiiwa Y, Misawa T, Harada N, Nawata H. (1992) EndothelinB receptor on guinea pig small intestinal smooth muscle cells. Am J Physiol 262:G308–G311.
    1. Young A, Wu W, Sun W, Benjamin Larman H, Wang N, Li Y-S, Shyy JY, Chien S, García-Cardeña G. (2009) Flow activation of AMP-activated protein kinase in vascular endothelium leads to Krüppel-like factor 2 expression. Arterioscler Thromb Vasc Biol 29:1902–1908.
    1. Yu JC, Pickard JD, Davenport AP. (1995) Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells. Br J Pharmacol 116:2441–2446.
    1. Zhang P, Covic L, Kuliopulos A. (2015) Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics. Methods Mol Biol 1324:191–203.
    1. Zhang Y, Li L, Hua Y, Nunn JM, Dong F, Yanagisawa M, Ren J. (2012) Cardiac-specific knockout of ET(A) receptor mitigates low ambient temperature-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Biol 4:97–107.
    1. Zhang YF, Jeffery S, Burchill SA, Berry PA, Kaski JC, Carter ND. (1998) Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma. Br J Cancer 78:1141–1146.
    1. Zhao XS, Pan W, Bekeredjian R, Shohet RV. (2006) Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 114:830–837.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa